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This thesis outlines an innovative solution for packaging an expansive set of theranostic 
agents for high-throughput intracellular delivery, which offers numerous advantages over 
liposomes and other contemporary encapsulation modalities. This encapsulation method works by 
using a simple 2-step phase-transfer chemistry. The first step consists of enveloping the agents 
within an inverted micelle capsule, and in the second step, they are repackaged with an outer lipid-
based shell to produce a structure termed the NanoCapsule (NCAP).   
Our encapsulation procedure is adaptable and robust, with modifiable size, chemistry, and 
surface properties and it is compatible with agents such as ions, small molecules, and ~10 nm 
nanoparticles. This method greatly simplifies hydrophobic encapsulation and surface 
modification, which is otherwise a costly and technically challenging procedure that relies on 
anaerobic reactions in an organic medium. Our encapsulation procedure can also be scaled with 
high-throughput efficacy. Furthermore, the inverted micelles and NCAP coating consist of 
materials that have been shown to provide excellent biocompatibility.  
With this methodology, agents are encapsulated without a significant amount of aqueous 
solvent in the lumen of the nanoparticle, thus, delivering a more concentrated and stable payload 
to the tumor site without the leaky tendencies of liposomal encapsulation. Within this thesis, we 
show how the NCAP architecture retains long-term stability and quantifiably enhances payload 
delivery intracellularly through in vitro and in vivo investigations. Furthermore, the highly 
customizable nature of our encapsulation methodology is especially desirable for theranostic 




methodology for encapsulating and delivering personalized theranostics, customized to match 
precise therapeutic needs. 
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Worldwide, several leading causes of deaths are classified as preventable diseases 
according to a study published in 2016.1 The statistics estimated for the top five leading causes of 
death in people below 80 years of age were identified as heart diseases (30% of 87,950 were 
preventable), cancer (15% of 63,209 were preventable), unintentional injuries (43% of 29,232 
were preventable), chronic lower respiratory disease (36% of 45,331 were preventable), and stroke 
(28% of 15,175 were preventable).1 The number of cancer cases worldwide has been projected to 
increase to 21.7 million new cases by 2030 (50% increase) with 13 million deaths (60% increase).2 
Despite this grim scenario, the death rate due to cancer decreased by 1.5% between 2005 and 2014 
while the overall cancer death rate fell by 25% between 1991 and 2014, which is equivalent to 
2,143,200 fewer deaths.3 This significant reduction in deaths from cancer can be largely attributed 
to increased access to medicine within developing countries and recent medical advances in 
diagnosis and therapy. 
Current State of Cancer Treatments and Their Challenges 
Modern hospitals have access to an array of cancer treatments such as surgery, exposure to 
radiation, chemotherapy, hormone therapy, immune therapy, and targeted therapy. The use of 
surgery to treat cancer can include advancements such as cryosurgery, lasers, or laparoscopy for 
minimally invasive surgery. However, the use of surgery often carries a great cost to the patient 
due to risks accompanied by pain, infections, bleeding, or reactions to anesthesia.4  
Radiation therapy is another form of treatment which close to two-thirds of all cancer 
patients receive, although the use of radiation has been linked to several serious side effects, 
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including damage to vital organs and microbiomes, and increased risk to subsequent cancers as 
indicated by radiation epidemiology studies.5  
The use of chemotherapy (small molecule drug agents) to target cancer cells is a common 
treatment method used to shrink tumors, followed by surgical excision with further rounds of 
chemotherapy. Unfortunately, this process is inherently destructive and invasive; it is also 
associated with several side effects such as weakness, nausea, loss of hair, and vomiting.6 
Furthermore, any healthy cells that show rapid division are also damaged in the process, thus 
causing further deterioration to the patient.7 
Overall, the current state of cancer imaging and treatment techniques is not yet perfect, but 
many treatments are balanced with predictable benefits and challenges. These challenges, as well 
as the referenced numbers of cancer cases and deaths, call for advanced treatment options to further 
minimize deaths that could have been preventable.8  
The Benefits of Nanotechnology in Medicine 
The field of “nanotechnology” (10‒9 meters) is opening new strategies in biomedicine that 
advance research towards the design of precise and personalized medicine.9 Specifically, 
nanoparticles have revolutionized personalized medicine by their ability to physically interact with 
tissues at the molecular level, either for therapy or imaging applications. Several advantages of 
delivering agents at the nanoscale level include enhanced bioavailability of poorly soluble agents, 
lower concentrations of drugs or imaging agents, prolonged systemic retention rates (which 
increases treatment activity), and higher absorption rates (due to facilitated delivery across the cell 
membrane).9 For these presumed benefits, a combined therapeutic and imaging-based approach, 
enhanced by nanotechnology, has been the target of considerable research.9 
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This field, known as nano-theranostics, uses a combination of nanomaterials combined 
with chemical modification and agent entrapment. Such dual-purpose theranostic nanoparticles 
can streamline therapeutic nano-medicine through simultaneous treatment of the disease and 
monitoring of the treatment progress with imaging techniques.10 The imaging modality depends 
on the type of nanoparticle; for example, the luminescent properties of carbon nanoparticles make 
them ideal for infrared imaging agents,11 whereas the surface plasmon resonance of different sized 
gold nanoparticles are excellent for photoacoustic imaging and photothermal ablation therapy.12 
For nanoparticles to function as theranostic agents, they must also effectively treat the target 
diseased tissue; this can be accomplished in several different ways. For example, some gold 
nanoparticles can be functionalized with tumor-targeting agents13 while tuned with a specific 
diameter that enhances surface plasmon characteristics, which allows them to generate heat when 
excited by light in the near-infrared spectrum (NIR).14,15 If these nanoparticles have been 
internalized within target cells and exposed to NIR light, the heat is able to destroy the cells, thus 
functioning as a photo-ablative agent.16 Another option is to use the nanoparticles as a vehicle to 
carry and deliver disease-treating agents via surface binding or entrapment, be it in ionic, small-
molecule, or pro-drug form.17 
The Role of Theranostic Nanoparticles towards Cancer 
Cancer is an extremely complex disease. For example, cancers across different patients, 
yet within similar tissue, can have very different phenotypic expressions of malignancy. This 
creates difficulties in treatment; inhibiting one element, such as vasculature growth, cellular 
receptors, or DNA, will not always have the same effect across all cells or affected patients.18 
Therefore, nano-theranostics must be personalized or redesigned for broad applications on several 
treatment levels, such as size/shape of particles, type of payload, material composition, and 
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delivery mechanism. The adaptability of nanoparticle design makes them an ideal platform for 
delivering personalized theranostics and allows for comprehensive preclinical studies of these 
agents.19 However, complex chemistries and synthesis procedures hinder the design of theranostic 
agents for efficient delivery towards a variety of disease types and patients. These considerable 
obstacles point to a need for a universal platform as part of the solution. 
The design of nanoparticles can involve programming of their physical properties, such as 
size, mass, and zeta potential, to facilitate different applications and targets. In passive targeting, 
the blood vessels of tumor cells are leakier than those of normal cells because of abnormalities in 
the basement membrane of cancer cells.20 The latter thus require higher levels of resources to 
continue propagation of the tumor mass. An additional problematic feature of tumors is poor 
lymphatic drainage, which is known as the enhanced permeability and retention effect (EPR). 
Consequently, the preferred dimensions for molecules to penetrate tumors via EPR and be retained 
long enough to treat the tumor mass efficiently is reported to be between 10‒150 nm.21,21 
The active version of cancer cell targeting is based on unique targeting proteins found on 
the cell membrane’s surface that differentiate them from healthy cells. In the active targeting 
approach, nanoparticles are engineered to possess targeting ligands for cell receptors on a specific 
type of cancer cell strain. Several other molecules that have been used to target nanoparticles 
include tumor-specific antigens, transferrin, growth factor receptors, nucleic acid aptamers, 
monoclonal antibodies, and death receptors.13  
With a combined design and targeting approach, the nanomedicine research community 
has developed a breadth of theranostic nanoparticles for various applications such as imaging, 
therapeutics, targeting, and enhanced delivery. For example, Jin et al. recently investigated an 
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intrinsic, biodegradable, and liposome-mimicking theranostic nanoparticle called the porphysome 
nanostructure. In their report, folate-conjugated porphysome nanostructures were designed to 
target folate receptors that are overexpressed in ovarian and breast cancer cells and initiate folate-
receptor-mediated endocytosis. Once the porphysome nanostructures disassembled within the cell, 
the authors used thermal ablation to destroy the cell while initiating photodynamic activity, which 
is monitorable with in vivo fluorescence microscopy.22  
In another example, Chen et al. designed peptide-modified ferritin nanocages and used 
them to target integrin αvβ3 on tumor cells. These protein-based nanoparticles were composed of 
24 subunits that assembled as a cage-like structure to deliver imaging agents (e.g., radiometal 
isotopes and fluorescent dyes) and therapeutic agents (e.g., photosensitizers and doxorubicin) to 
tumor cells.23 The nanocages were co-loaded with copper-precomplexed doxorubicin and a near-
infrared dye (ZW800) to demonstrate an augmentation of optical imaging and chemotherapeutic 
effects in mice models.24,25 
A 2014 study by Liu et al. investigated pH-sensitive theranostic nanoparticles designed for 
both magnetic resonance imaging (MRI) and therapy. The particles were developed by the use of 
multi-block polymer poly(lactic acid)-polyethylene glycol-poly(L-lysine)-diethylenetriamine 
penta-acetic acid and the pH-sensitive material poly(L-histidine)-polyethylene glycol-biotin. This 
polymer nanoarchitecture was used to encapsulate the anti-hepatocellular carcinoma drug 
sorafenib and MRI-active Gd-DTPA (Gadopentetic acid), while antibodies were used 
simultaneously to facilitate VEGFR (vascular endothelial growth factor receptor) targeting. The 
results of nanoparticle treatment in mice xenografted with the H22 tumor cell line showed higher 
MRI resolution and imaging time with an increased treatment efficacy of the tumor as compared 
to the contrast agent Magnevist®, which is used with MRI to visualize lesions.26  
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Nanoparticles and the Importance of Nano-Delivery 
As we have discussed here, nanoparticles offer a versatile vessel for the transportation of 
various agent types and material compositions. Without such a delivery vehicle, imaging or 
therapeutic agents would suffer on several dimensions that nano-delivery strategies can alleviate, 
such as increased half-life of systemic clearance, bioavailability, controlled release, and 
active/passive targeting.27 Therefore, each application must use a carefully designed and versatile 
nano-delivery system to achieve a specific purpose, either for imaging or therapy. There are several 
popular nano-based delivery systems such as liposomes, polymeric micelles, dendrimers, 
nanospheres, nanocapsules, inorganic nanoparticles, protein-derived nanoparticles, and nanotubes. 
Liposomes are lipid bilayers that enclose water-soluble agents within the nanoparticle’s 
hydrophilic core, whereas micelles can package water-insoluble agents within their hydrocarbon-
rich hydrophobic core. Another classification of nanoarchitectures includes dendrimers, which are 
defined as branched, three-dimensional, tree-like structures developed from artificial or natural 
materials such as nucleotides or sugars. Dendrimers can be loaded with agents to target cancer 
cells, whereas their branching nature is also convenient for conjugating several molecules on the 
surface. Nanospheres are matrices infused with agents and functionalized with targeting ligands.  
While, nanocapsules have a lipid shell with a central core composed of polymers or other fatty 
molecules, which enables efficient packaging of agents for systemic delivery.9 
Apart from polymers or lipid-based systems, inorganic materials can also be explored as 
nano-delivery vehicles. For instance, non-polymer or non-lipid based nano-delivery vehicles 
include monodisperse inorganic nanoparticles such as gold or iron oxide nanoparticles. These 
inorganic nanoparticles have strong zeta potentials and a large surface-area-to-volume ratio, which 
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makes them easily passivated with theranostic agents. Furthermore, inorganic nanoparticles are 
well known for their strong covalent surface modification properties.27 Biomolecules such as 
proteins are also considered as nano-delivery systems on account of their biocompatibility, 
biodegradability, and surface modification ability.23 For example, albumin is used as a nanocapsule 
in the FDA-approved drug Abraxane to deliver the water-insoluble chemotherapeutic agent 
Paclitaxel for cancer therapy.23 
The most popular nano-delivery vehicles for theranostic applications are liposomes. These 
nanoparticles offer advantages such as transport of water-soluble agents where their inherent 
nanoarchitectural properties make hydrophilic molecules face the core, and hydrophobic 
molecules are kept within the lipid membrane. Liposomes are ideal for systemic use because of 
their biocompatibility, ability to self-assemble, large loading capacities, and their ability to be 
modified for different theranostic applications.28 
One of the most cited case studies showing the success of liposomal use for systemic cancer 
treatment is the pharmaceutical product called Doxil® (Ben Venue Laboratories, Inc., Bedford, 
OH), which was granted FDA approval in 1995. Doxil is a liposome packed with the anti-cancer 
drug doxorubicin and has been mainly used in the treatment for breast cancer and other aggressive 
tumors. Doxil has increased circulation time and higher treatment efficacy at lower concentrations 
when compared to treatment using unpackaged doxorubicin alone (Ben Venue Laboratories, Inc., 
Bedford, OH).  
While several liposome-based delivery methods have been advantageous in the therapeutic 
world, liposomes have several limitations that restrict their effectiveness for theranostic 
applications. First, liposomes tend to be “leaky,” which is defined as the passive and unintentional 
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release of the contents. This “leakiness” depends on several variables such as drug-to-lipid ratio, 
vesicle diameter, and cholesterol content.29,30 Therefore, the “leakiness” reduces the efficiency and 
potency of drugs or agents needed to reach their desired targets, decreasing their overall therapeutic 
effectiveness and potentially contributing to unintended side effects. Furthermore, liposomes are 
foreign objects that are quickly cleared by the reticuloendothelial system (RES). Coating of 
liposomes with polyethylene glycol (PEG) can increase stability and minimize the uptake by 
RES;31 however, pegylation hinders the particles’ controlled release ability at the intended 
tissue.32,33 Unfortunately, as current research advances the complexity of liposomal architectures, 
and as theranostic agents become more intricate to serve a variety of purposes, the nanoparticles’ 
complex chemistry and synthesis procedures hinder their ability to move into clinical trials and 
become FDA approved.28 
The Need for a Redesigned Nano-Architecture 
One significant barrier of nano-theranostics that limits their translation into clinical 
applications is the lack of a broad platform for encapsulation and delivery of the theranostic agents. 
Current research is continuously producing novel theranostic agents of several calibers, with 
various applications, and with high possibilities to revolutionize modern medicine. Yet, the use of 
novel theranostic agents in practice is often hindered by their inability to properly reach their target 
with high bioavailability and biocompatibility, even with the aid of popular nano-delivery 
techniques such as liposomes. Nonetheless, an ideal, universal, and biocompatible nanoparticle for 
multi-purpose, high-throughput delivery has yet to come to fruition. Despite the progress in this 
field, there are several challenges that must be improved, such as the development of a robust 
package with high packaging capacity, simpler chemical synthesis, material compatibility with 
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molecularly diverse agents, material biocompatibility with cells, and ligand conjugation 
efficiency.34  
From our research, we believe that a universal nanoparticle – with significant 
improvements in the delivery throughput of theranostic agents – can be achieved by a two-pronged 
approach, which are i) the development of a highly efficient, robust, and universal vehicle for 
theranostic agent encapsulation; and ii) the wrapping of the encapsulated agent with a modifiable, 
stable, and biocompatible shell. 
Development of a highly efficient, robust, and universal vehicle for theranostic agent 
encapsulation 
To address this methodology, we looked towards the use of inverted micelles for their ease 
of preparation, encapsulation, and versatility with various materials.35 By definition, regular 
micelles are self-assemblies of amphiphilic molecules in an aqueous medium, whereas inverted 
micelles are self-assemblies of amphiphilic molecules in an organic medium. Such inverted 
micelles have been explored as encapsulating systems for hydrophilic agents,35 yet are not 
exhaustively investigated regarding in vitro or in vivo agent delivery. To highlight the effectiveness 
of inverted micelles as robust encapsulation and delivery systems, one study performed 
spontaneous acid-base self-assembly to achieve nano-encapsulation of small molecules and 
inorganic nanoparticles that circumvented the use of chemical modification.36 The first subject for 
phase transfer into the organic solvent toluene was a fourth-generation amine-terminated PAMAM 
dendrimer (G4–NH2) passivated with the hydrophilic organic dye, methyl orange (previously 
unable to transfer into toluene). The inverted-micelle-initiating molecule was a dodecanoic acid, 
which electrostatically interacts with the amine-terminated PAMAM dendrimer. The use of UV-
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vis spectroscopy confirmed the nearly complete transfer of the dye into toluene containing >10% 
dodecanoic acid. This inverted micelle encapsulation was pursued with Pd nanoparticles and 
proved successful.36 A second article expanded on Chechik et al.’s work with the formation of 
supramolecular, hyperbranched polyethyleneimine (PEI) with encapsulation with other fatty acids, 
showing the versatility and possibilities of this mechanism to encapsulate water-soluble agents 
efficiently within organic solvents.37  
To highlight the robust packaging ability of inverted micelle structures, Qiu et al. found 
that the use of amphiphilic phosphazene polymers in an inverted micelle form was able to retain 
70% of its packaged contents over a 60-day period as compared to regular poly(lactide-co-
glycolide) (PLGA) microparticles, which only retained 50% of the enclosed agent within the first 
day.38 Thus, the inverted micelle architecture showed robust encapsulation and retention abilities; 
unfortunately, this study did not address critical factors such as systemic retention time, 
biocompatibility, and ability to encapsulate multiple agent types and material compositions. 
To highlight an example of protein encapsulation in inverted micelles, Miller et al. studied 
micelles composed of a hydrophilic and hydrophobic block-copolymer (ϵ-caprolactone)-block-
poly(2-vinyl pyridine) (PCL-b-P2VP), which were used to transfer model globular proteins 
between aqueous and organic (toluene) phases. Thus, such polymer-based inverted micelles could 
also serve as nano-encapsulation vehicles.39  
Wrapping of the encapsulated agent with a modifiable, stable, and biocompatible shell 
In a previous section, we saw that lipids are ideal wrapping agents for systemic nano-
delivery vehicles on account of stability and biocompatibility.40 Hence, here we venture into 
combining the use of lipids as a shell to wrap the inverted micelle capsule to create a modified 
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version of nanocapsules, which we have termed the NCAP,  NanoCS, AI-NP, or NMC depending 
on the project and application. With this combined architecture consisting of a robust inverted 
micelle capsule wrapped with a biocompatible lipid shell, many types of agents would be capable 
of being efficiently entrapped and become subject to high-throughput systemic delivery. 
For example, the use of inverted micelles is not challenged by encapsulating hydrophobic 
or hydrophilic agents because hydrophobic molecules can occupy positions between the 
hydrocarbon sections of the lipids and the inverted-micelle-initiating molecule, while hydrophilic 
molecules can be enclosed within the micelle’s hydrophilic core. Furthermore, an appropriate 
selection of a molecule that initiates the inverted micelle in an organic medium can facilitate the 
incorporation of a diverse range of molecules of various charges, chemical structures, or weights. 
Specific Aims 
Within this literature review, we have seen examples of current research discussing the 
advantages of inverted micelles and their packaging efficiency with small molecules, inorganic 
nanoparticles, and biological material. We have also discussed the difficulties associated with 
creating ideal nano-architectures built with materials suitable for clinical translation. Therefore, 
with these factors in play, we believe that this area of research is ripe for disruption with the novel 
nanoarchitecture that we have termed the NanoCapsule. 
This thesis will outline an innovative approach for creating a novel nanoparticle 
architecture with robust chemistry with a streamlined 2-step process adaptable for a variety of 
agents. By using phase transfer to facilitate hydrophobic modification and lipid wrapping, this 
approach has the potential to eliminate many of the challenges facing encapsulation of chemically 
different theranostic agents. Furthermore, the proposed approach uses materials with proven 
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biocompatibility, which greatly improves the prospects for similar methodologies needing FDA 
approval. The overarching goal of this thesis seeks to create a universal and highly efficient 
encapsulation and delivery vehicle, which can be used to overcome the barriers of current clinical 
techniques. Ideally, this research is an advantageous step in facilitating the use of theranostic 
agents in personalized medicine for the entire nanomedicine community. We have followed the 
following aims to defend our hypothesis: 
Aim 1: Develop an efficient nanoparticle architecture capable of encapsulating and delivering 
various types of agents 
For this aim, we engineered a novel encapsulation nanoarchitecture, developed and 
optimized synthesis methods, and characterized the physical and material properties of the 
nanoparticles. The facile 2-step process began with an aqueous-to-organic phase transfer used to 
envelop agents within an amphiphilic hydrocarbon-based inverted micelle. The resulting 
encapsulation depends on the electrostatic reactions between charged heads of fatty acids, such as 
dodecanoic acid, or fatty amines, such as dodecylamine, and the charge of the encapsulated agent. 
This approach could efficiently create a robust hydrophobic shell to protect the packaged agents 
from leakage and harsh denaturing environments. 
Aim 2: Determine the ability of nanoparticle architecture to encapsulate specific types of agents 
After developing and optimizing the methodology to create the NCAP, we tested its 
encapsulation capability with six different types of agents that have potential theranostic 
applications: cesium ions (Cs+), silver ions (Ag+), a small molecule drug (doxorubicin), inorganic 
gold nanoparticles (AuNPs), and organic carbon nanoparticles (CNPs). Each of these agents has 
very different chemical and functional properties and applications that span anti-cancer therapies, 
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nano-imaging, and even anti-microbial remedies. The variety of agents’ characteristics will, 
therefore, thoroughly test the adaptability of our novel delivery vehicle. 
Aim 3: Evaluate the theranostic potential of encapsulated agents 
Once the protocols have been optimized, and the nanoarchitecture characterized, each type 
of encapsulated agent was tested for their effectiveness in a biological setting.  
Within our first project, we published an article in 2016 where we investigated the 
intracellular delivery of cesium chloride (CsCl) through the nanocapsulation technique mentioned 
above and compared it to the unamended cesium salt towards cancer therapy. The nano-based 
system, which we termed NanoCs (for Nano-Cesium), proved to be more efficient at intracellular 
delivery of cesium ions as compared to the unamended salt alone, and the mechanism for cancer 
therapy was glucose uptake inhibition rather than the expected high-pH therapy. This nanoparticle 
containing ionic cesium was developed for the first time for delivery to tumor cells in vitro as well 
as in vivo.41 
To address antibiotic resistance on the nano level, our team designed a unique 
combinatorial approach to impair antimicrobial activity by encapsulating ionic silver within the 
inverted-micelle-initiated nanocapsule and wrapping the encapsulated agent with a lipid-based 
levofloxacin prodrug; we termed this new nanoarchitecture AI-NP (for Ag ion-nanoparticle). Our 
rationale was to use the antimicrobial activity of silver ions to disrupt the bacterial cell wall and 
deliver the topoisomerase inhibitor molecule levofloxacin in the form of a prodrug cleavable by 
common intracellular esterases. 
As outlined, the liposomal anti-cancer agent Doxil has many weaknesses; therefore, we 
investigated the encapsulation, treatment efficiency, and imaging capabilities of inverted micelle 
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(NCAP) containing doxorubicin and the popular small-molecule fluorescent probe Rhodamine. 
Here, we visualized the interactions of the NCAP with a breast cancer cell line through various 
fluorescent imaging modalities and analyzed the NCAP’s effectiveness as cancer therapeutic 
compared to treatments with free doxorubicin or doxorubicin within a liposome. 
Finally, we recently published an article delving into nanoparticle-based imaging with 
separate encapsulations and treatments of surface-plasmon-rich gold nanoparticles or Raman-
active carbon nanoparticles. We focused on ~10 nm gold and carbon nanoparticles because such 
small particles are usually unable to activate enough receptors for receptor-mediated 
endocytosis.42,43 These nanoparticles were encapsulated within nanocapsules, termed NMCs (for 
Nano-MultiCapsules), in a simple 2-step process to form a unique particle-in-particle complex. 
We found that the NMCs enable efficient encapsulation of numerous ~10 nm nanoparticles for 
high-throughput intracellular delivery within a breast cancer cell line.44 
In the following chapters, we will cover each project in depth with details on the 
motivations behind each project, their methodologies, and the explanation of how the novel NCAP 
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The use of cesium chloride (CsCl) for cancer therapy (“high pH therapy”) has been 
theorized to produce anti-cancer properties by raising intracellular pH to induce apoptosis. 
Although considered as “alternative medicine”, little scientific evidence supports this theory. 
Alternatively, cells have no cesium ion (Cs+) mediated channels for clearance. Thus, such unstable 
electrochemical distributions have the potential severe potential to disrupt electrochemical 
dependent cellular processes, such as glucose co-transporters. Hence, a detailed investigation of 
pH changing effects and glucose uptake inhibition are warranted as a possible cesium-induced 
anti-cancer therapy. We developed and characterized cesium nanoparticles (38 ± 6 nm), termed 
NanoCs, for nanoparticle-mediated internalization of the ion, and compared its treatment to free 
CsCl. Our investigations suggest that neither NanoCs nor CsCl drastically changed the intracellular 
pH, negating the theory. Alternatively, NanoCs lead to a significant decrease in glucose uptake 
when compared to free CsCl, suggesting cesium inhibited glucose uptake. An apoptosis assay of 
observed cell death affirms that NanoCs leads tumor cells to initiate apoptosis rather than follow 
necrotic behavior. Furthermore, NanoCs lead to in vivo tumor regression, where H&E analysis 
confirmed apoptotic cell populations. Thus, NanoCs persuaded pH-independent anti-cancer 
therapy by inducing metabolic stasis. 





High pH therapy (also known as “cesium therapy”) is an alternative cancer treatment 
approach,1 wherein the cesium chloride (CsCl) salt is taken orally or injected intravenously and 
intended to raise the intracellular pH of tumor cells leading to cell-mediated apoptosis. Changing 
the acidic pH range of the cancerous cells towards weak alkalinity is expected to imperil its 
endurance by neutralizing and excluding the generation of essential acidic proteins and molecules. 
This theory has been tagged as an “Underground Cure for Cancer”1–3 although scientific evidence 
is severely lacking. Not to be confused with conventional and orthodox cesium-137 radiation 
therapy,4 or nano-enabled extracellular pH modulation,5 “cesium therapy” is mostly prescribed by 
nutritionists and pseudo-doctors. Existing studies of CsCl therapy report patient and animal 
consumption of CsCl leading to a decrease in symptoms and pain,6–8 Although most of these 
patients were terminal cases, a post-mortem follow-up autopsy revealed cesium accumulation 
within vital organs. 9 Investigations into the health risks of high CsCl consumption have shown a 
direct correlation to cardiac arrhythmia,9–12 hypokalemia,13 and death,9,10 In response to these 
health risks, many licensed physicians emphasize that cesium therapy should not be used to treat 
tumors until further research has been conducted.  
Besides “high pH therapy”, other scientific reports have indicated CsCl interacts with 
important ion dependent cellular mechanisms 13,14 which are upregulated in cancerous systems and 
as such pose as potential targets for tumor inhibition. One possible mechanism to investigate uses 
Cs+ to disrupt the ion dependent facilitated glucose transport proteins (GLUT) (sodium 
(Na+)/glucose co-transport proteins), which are overexpressed in tumor cells.15 An increase in 
inner membrane charge by Cs+ exposure could reduce, Na+/K+ channel activity leading to a 
decreased amount of Na+ and glucose influx via the Na+/glucose cotransport proteins. This decline 
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in glucose influx, if significant, can result in cellular starvation and apoptosis initiation, thus 
deeming Cs+ a metabolic therapy agent. A strong indication of starvation is the production of 
reactive oxygen species (ROS) which can lead to intracellular damage and oxidative stress, and 
thus cellular autophagy.16 One known ROS target of interest is the aforementioned Na+/K+ 
pump17,18 which indirectly aids Na+/glucose cotransporters by increasing extracellular Na+ and 
thus leads to a chain reaction of starvation-mediated apoptosis. 
The free CsCl salt lacks specific tumor targeting tactics, whether taken orally or 
intravenously as its transport is purely determined by diffusion, physiological filtration, and 
immune recognition. Due to its high water solubility (1865 g/L at 20 °C) the free ions are left to 
interact throughout all reliant systems including normal bystander cells, posing detrimental effects 
that can lead to severe off target toxicity.11–13 To address this issue and to further investigate the 
role of CsCl in metabolic therapy, a nanomedicine approach was envisioned, since nanoparticles 
tend to accumulate passively in tumor tissue much more than normal tissues.19–23 This is due to 
the rapid and entropic metastasis of in vivo tumor growth which leads to poor formation of blood 
and drainage vessels in adjacent tissue; a phenomenon commonly known as the enhanced 
permeability and retention effect (EPR).24 Nanoparticles of certain sizes tend to accumulate 
passively in tumor tissue much more than they do in normal tissues.19–23 Towards this aim, we 
developed a nanoparticle of ionic cesium (NanoCs) for delivery to tumor cells in vitro and in vivo 
for the first time. The NanoCs particle was used to investigate any possible intracellular pH change 
from intracellular delivery of ionic cesium, mechanistic influence on glucose uptake and ROS 
generation, as well as method of cellular death. Furthermore, in vivo studies revealed significant 




Results and Discussion 
Design of Cesium Based Nanoparticle and Subsequent Analysis of Metal Entrapment, 
Optimization, and Stability 
NanoCs was prepared following a synthetic procedure to encapsulate and trap a high 
concentration of cesium ions (Cs+) within polymeric micellar particles with excellent retention and 
stability. Polymers were chosen based on their ability to capture high quantities of agents varying 
in molecular structures from small molecules25,26 and peptides.21,27 These vast interstitial spaces 
combined with strong negative charges associated with the poly acrylic acid residues create a 
favorable environment for entrapment of the positively charged cesium ions. The process involves 
the stepwise formation of a micelle from polyethylene glycol cetyl ether (2 mg/ml, Average Mn 
1124) in a CsCl/water solution and subsequent addition of a solution of poly(styrene)67-block-
poly(acrylic acid)27 in THF (Figure 2.1). The water to THF volume ratio was optimized to 4:1 for 
ideal particle formation, size, and long-term stability. In order to maximally enrich Cs+ within the 
particle, various amounts of the salt were applied during particle synthesis (0, 10, 20, 50, and 100 
mg/ml). Using dynamic light scattering (DLS), we identified that the salt concentration limit to 
produce stable particles was 50 mg/ml and produced NanoCs with an average hydrodynamic 
diameters (Dhy) at 38 ± 6 nm accompanied by a polydispersity index of 0.2 ± 0.0 (Figure 2.2 and 
Figure 2.3). Higher concentrations of CsCl during particle synthesis resulted in polymeric particles 
with a Dhy of 548 ± 229 nm accompanied by a high polydispersity index of 0.8 ± 0.1 (Figure 2.2). 
Control particles (CP) lacking Cs+ (Dhy: 19 ± 4 nm with a polydispersity index of 0.3 ± 0.0) (Figure 
2.3) were produced via the same methods (using 18 MΩ nanopure water instead of the CsCl 
solution). CP was used as controls during various experiments to ensure that polymer interaction 
and surface chemistry did not interfere with experimental hypotheses. To eliminate any free Cs+ 
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ions present, post particle synthesis, NanoCs underwent dialysis for a prolonged period and 
subsequently filtered. To confirm the presence of cesium, energy dispersive X-ray spectroscopic 
measurements (EDS) on anhydrous particles imaged via SEM, enabled us to see cesium signals 
within NanoCs particle mass (Figure 2.4, Figure 2.5). In order to quantify the cesium entrapped 
within NanoCs post dialysis, a hydrochloric acid digestion of the particles followed by inductively 
coupled plasma optical emission spectrometry (ICP-OES) measurements were performed. This 
data showed that the NanoCs had a capture efficiency of 250 Cs+ per nanoparticle or 1:0.21 weight 
per weight (w/w) of nanoparticle to Cs+ respectively which remained constant during long-term 
shelf storage at ambient temperature. Quantitative analysis of cesium release, post dialysis 
revealed that ~85% of cesium discharged within 72 hours (Figure 2.6). This cesium release can be 
described as a two-phase release system, whereby the first burst discharged 42% of the cesium ion 
within 8 hours of dialysis, which was followed by an extended cesium release of 43% over the 
next 64 hours. A Zeta analysis of the particle’s electrophoretic potential () showed that both the 
NanoCs and CP have a negative surface charges (-24 ± 4 and -42 ± 5 mV, respectively). Since 
both particle variants (CP and NanoCs) had zeta potentials below -20 mV, they are predicted to 
have strong colloidal stability28,29 (Figure 2.7). Furthermore, the significantly more negative  of 
CP compared to NanoCs indicates that NanoCs will have a lower probability of developing a 
protein corona before reaching its intended target.30 Anhydrous diameter (Dah) and morphology of 
NanoCs particles were assessed by Transmission Electron Microscopy (TEM). These TEM 
micrographs determined that CP and NanoCs both possess spherical traits in nature (Figure 2.8, 
Figure 2.9) and furthermore displayed Dah of 25 ± 6 and 27 ± 6 nm, respectively as measured by 
ImageJ analysis (n=100 each) (Figure 2.10). NanoCs and CP were analyzed for Dhy stability over 
the course of 30 days (stored at 4 °C) and were found to maintain significant integrity (Figure 
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2.11). In order to assess its systemic stability, hydrodynamic diameter of both NanoCS and CP 
were monitored over the course of 7 days at 37 °C in pH 4.5 (HCl), 7.4, and 12 (NaOH), nanopure 
water (0.2µm), and fetal bovine serum (FBS, 10%). Over the course of one week, CP integrity 
remained consistent (Figure 2.12), while NanoCs particle diameter increased slightly in lower pH 
but persisted under other conditions (Figure 2.13). This result ensured the systemic stability of the 
particles minimizing the possibility of aggregation. 
Cesium’s high atomic z number (z=55) led to an increased electron density within NanoCs 
particles which could be observed via electron microscopy, as compared to organic moieties 
consisting of carbon, hydrogen, and oxygen that are found in CP (as confirmed by FTIR (Figure 
2.14, Figure 2.15) and Raman spectrometry (Figure 2.16a, b)). Further ImageJ analysis on TEM 
images revealed that the contrast within CP was orders of magnitude higher than NanoCs (Figure 
2.17). This difference in white (high intensity) versus black (low intensity) pixels indicates that 
NanoCs particles have a higher atomic density due to the presence of cesium ions (z=55) and thus 
leads to a lower pixel value within TEM micrographs. After hydrated and anhydrous state 
characterization through light scattering and electron microscopy, atomic force microscopy (AFM) 
was used to determine particle height and surface topography (Figure 2.18). The measured CP and 




Figure 2.1: Schematic representation of NanoCs synthesis. Cs+ ions interact with negatively 


























































Figure 2.3: Overlaid histogram representing the number averaged (%) of CP and NanoCs particles. 
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Figure 2.6: a) NanoCs Cesium release profile over the course of three days as measured by ICP-





Figure 2.7: Surface charge as measured by Zeta potential of CP and NanoCs. Student’s T test was 







































Figure 2.8: TEM micrograph of CP. Within the figure is an inset of a particle at higher 
magnification for detail.  
 
Figure 2.9: TEM micrograph of NanoCs. Black arrow shows cesium collection within NanoCs 
































Figure 2.11: Long term shelf life stability analysis (measured over 30 days) of CP and NanoCs 
hydrodynamic diameter. X-axis is in Log2 scale. 
 
  

































Figure 2.12: Hydrodynamic diameter stability of CP in various environments measured over the 
course of seven days. 
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Figure 2.13: Hydrodynamic diameter stability of NanoCs in various environments measured over 
the course of seven days. 
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Figure 2.14: FTIR analysis of CP composition. (a) Near-mid infrared spectrum of respective 
samples. (b) Near-infrared spectrum close up of black boxed outline in (a). Peaks are assigned to 





Figure 2.15: FTIR analysis of NanoCs composition. (a) Near-mid infrared spectrum of respective 
samples. (b) Near-infrared spectrum close up of black boxed outline in (a). Peaks are assigned to 





Figure 2.16: Raman analysis of (a) CP and (b) NanoCs composition. Peaks are assigned to common 





Figure 2.17: ImageJ analysis of pixel intensity of particles TEM micrographs (white pixel = high 
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Biocompatibility Profile and Cellular Response to Cesium Chloride and NanoCs Treatments 
To fully capitalize on the in vivo nanoparticle – EPR effect combination, an in vitro 
biocompatibility assay was necessary to understand NanoCs and free CsCl toxicity. An estrogen 
receptor positive, human breast cancer cell line (MCF-7) was cultured in triplicate at a density of 
10,000 cells per well for cytotoxicity measurements via MTT reduction assay. MCF-7 cells were 
treated with various concentrations of CsCl from 1000 µM to 15.6 µM. NanoCs samples used to 
treat cells were calculated at a CsCl equivalence concentration from 1000 µM to 15.6 µM based 
on concentrations of Cs+ within particles as determined by ICP-OES. Finally, CP samples used to 
treat cells were calculated based on volume equivalence of NanoCs samples, in order to keep 
particle concentration, the same (Figure 2.19). Cell viability, as measured by percent difference 
from control, in the presence of free CsCl returned a 48-hour exposure IC50 of 250 µM, while 
NanoCs showed significantly higher toxicity with a 48 hour IC50 of 77 µM (Figure 2.20, Figure 
2.21). As expected, MCF-7 cells remained largely unresponsive to CP samples. These variations 
in cell viability between free CsCl solution and NanoCs are considered biologically significant 
with a p-value less than 0.001. As a result, we can conclude that NanoCs is outperforming the 
delivery of Cs+ ions to the cells.
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Figure 2.19: Bright field images of MCF-7 cells at 20X. The treatment concentration is 62.5 µM 





Figure 2.20: Cell viability of NanoCs, CP, and CsCl as a percent ratio to control cells. 
Concentrations of NanoCs were treated in molar equivalence to CsCl, and CP was treated in 
volume equivalence to NanoCs. 
 
  

























Figure 2.21: Bar graph detailing IC50 values of NanoCs as compared to CsCl alone (t-test for 





Further investigations into the cellular entry mechanisms of NanoCs particles were 
performed via independent endocytic inhibitors to predict the primary internalization pathway. Of 
inhibitors, we considered clathrin mediated entry inhibition by chlorpromazine and Dynasore, 
clathrin-independent endocytosis inhibition by Nystatin, and energy dependent uptake inhibition 
by sodium azide with 2-deoxyglucose (NaN3/DOG). Since NanoCs internalization directly 
correlates to cell viability, we used an MTT reduction assay to compare inhibition effects with 
control samples. MCF-7 cells were first exposed to inhibitors for one hour before dPBS washing 
and 24 hour NanoCs incubation (Figure 2.22). Chloropromazine, a clathrin protein translocator,31 
nystatin, a caveolae disassembly agent,32 and NaN3/DOG, an inhibition combination of 
glycogenolysis and cellular respiration,33 all showed the highest cell viability. Contrarily, 
dynasore, an inhibitor of dynamin dependent clathrin mediated endocytosis,34 showed lower cell 
viability compared to the other formulations. This information indicates that the NanoCs particle 
is versatile transportation vehicle for cellular internalization and takes part in multiple endocytic 
pathway for delivering cesium ions within the cell.
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Figure 2.22: Investigations of NanoCs mechanism of cellular internalization. a) Control cells 
treated with inhibitors of various endocytic pathways. b) Cells treated with endocytic inhibitors 





Experimental Validation of Proposed ‘High pH Therapy’ Theory 
A common assumption, of CsCl when used as an “alternative therapy”, was that free Cs+ 
would lead to an increase in intracellular pH where cellular mechanisms cease leading to cell 
death.6–8 Experimental proof in support of this mechanism is rather weak as conflicting literature 
reports exist.6–8 However, it was theorized that the acidic nature of tumor cells, due to high cellular 
activity and glucose decomposition to lactic acid (also known as the Warburg effect35), will cause 
the cell membrane to act as a moderately strong electron donor and thus drastically enhance the 
permeability for Cs+ 6,8. As a salt, CsCl does not have the ability to change the pH of neutral water 
due to its role as a spectator ion. To grasp CsCl’s effect on a low pH solution, an unbuffered 
nanopure water sample was decreased to pH 4.1 with hydrochloric acid and monitored via pH 
probe while supplemented with the gradual addition of CsCl salt. Interestingly, as the 
concentration of CsCl increased, we observed the pH of the system moderately increase until it 
reached 300 mM and subsequently flat lined without surpassing pH 4.8 (650 mM being the 
maximum concentration tested) (Figure 2.23). This noticeable increase in observed pH can be 
explained by the Debye-Huckel equation (Equation 2.1), whereby increasing the ionic 
concentration of a solution decreases the activity of the hydrogen ions, not the actual content36–38.  




Will the decline in hydrogen ion activity via CsCl exposure lead to anti-cancer properties? The 
observed pH phenomena raised a larger issue regarding the extraneous amount of CsCl needed to 
reduce the activity of hydrogen ions in a non-buffered environment by a few units. Knowing that 
cells contain natural buffers, a large intake of this salt could lead to various other cellular issues 
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before hydrogen ion activity decreases enough for the theorized pH-driven apoptosis becomes the 
cause of cell death.  
 
Figure 2.23: Dot plot of CsCl concentration versus pH when added to pH 4 water. 
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To further probe any possible intracellular pH change due to decreased hydrogen ion 
activity during CsCl exposure, the cell permeable pH sensitive fluorescent dye carboxy 
seminaphtharhodafluor (SNARF-1), was used to quantify NanoCs and CsCl pH transitions within 
the MCF-7 breast cancer cell line. Carboxy SNARF-1 (Figure 2.24) is known to alter its 
fluorescent properties under different cellular pH conditions.39 SNARF-1 produces an emission 
peak at 585 nm (green fluorescence) for acidic conditions (maximum emission at pH 6) and 640 
nm (red fluorescence) for basic conditions (maximum emission at pH 9) when excited at 488 nm. 
Before confocal imaging, MCF-7 cells were exposed to SNARF-1,40, washed and then treated with 
respective samples at 100 µM CsCl, 100 µM CsCl equivalent of NanoCs, and CP at NanoCs 
volume equivalence. Treated cells were incubated at 37 °C and 5% CO2 for 4 hours, then washed 
and fixed for confocal imaging. All images in the 585 emission window were corrected for cellular 
auto-fluorescence (Figure 2.25a-j). A non-cancerous breast cancer cell line (MCF-10A) prepared 
in a similar fashion, was loaded with SNARF-1 and imaged as a positive control since non-
cancerous cells possess a close to neutral intracellular pH as compared to the acidic intracellular 
nature of tumor cells (Figure 2.25i-j). Confocal images and intensity quantifications were 
performed by a Zeiss 700, 20X objective, with gain and laser power consistency among all 
samples. The ZEN Blue image processing program was used to quantify MCF-7 intensity readings 
per pixel and revealed that the pixel intensity peak ratio (PIPR) of protonated (acidic environment) 
to the deprotonated (basic environment) form of SNARF-1 did not drop below 2 (Figure 2.25b, d, 
f, h, Figure 2.26) indicating that the amount of Cs+ delivered did not significantly change the 
intracellular pH. Given that we had delivered Cs+ above IC50 value (70 µM), any higher 
concentrations of CsCl would have led to cellular death and unreliable SNARF-1 intensity 
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comparisons. As expected, the non-malignant MCF-10A cell line produced a much lower PIPR 
value (0.29 ratio of deprotonated to protonated SNARF-1) (Figure 2.25i, j). 
 





Figure 2.25: SNARF-1 confocal images and pixel intensity peak analysis of MCF-7 and MCF-
10A for investigations into possible CsCl induced pH change. (a-h) Confocal images of MCF-7 
cells loaded with SNARF-1 and treated with respective samples at 100 µM of CsCl concentration 
equivalence. b, d, f, h, and j is each treatment’s unmodified pixel intensity with calculated peak 
ratios. (i, j) Positive control of SNARF-1 loaded MCF-10A cells (non-cancerous cell line) with a 





Figure 2.26: Bar chart of respective samples PIPR value. 
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Investigation of NanoCs for Metabolic Therapy 
In oncology, the Warburg effect35 states that the high metabolic activity of cells is an 
incident characteristic of malignant cancer which leads to a vast and rapid consumption of the 
energy molecule adenosine triphosphate (ATP) necessary for rapid cellular division. As a result, 
tumor cells upregulate GLUT expression to keep up with glucose intake for ATP generation.15 
This consequence makes the targeting and inhibition of the GLUT pathway an area of high interest 
for treating basic to malignant forms of cancer. The GLUT pathway, and more specifically the 
Na+/glucose cotransporter, is highly dependent on the electrochemical gradient, which can be 
disturbed if there was an imbalance of charges across the membrane due to an intake of foreign 
ions, or any disruption in Na+/K+ pump activity. 
Internalization of Cs+ (a positive ion), via NanoCs uptake, might initiate the destabilization 
of the electrochemical gradient as cells have no viable means of clearing Cs+ from their system, 
and it would contribute to the internal membrane charge. Additionally, since CsCl leads to a 
decrease of free K+,13,14 which reduces the extracellular transport of Na+ by the Na+/K+ pump, the 
Na+/glucose cotransporter could cease to replenish the cells energy source and lead to cellular 
starvation.41 Thus, metabolic therapy in the form of Cs+ via reduction of GLUT activity could 
result in metabolic stasis, and induce cellular apoptosis. 
To further examine this phenomenon, we used the fluorescently labeled marker 2-deoxy-
2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose (2-NBDG) to visualize and quantify 
glucose uptake. This fluorescent 2-deoxy glucose analog has the ability to accumulate within living 
cells since it cannot be fully utilized in glycolysis following phosphorylation by hexokinase. 
Hence, 2-NBDG makes for an optimal marker in identifying any incidental glucose uptake 
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inhibition. An initial culture of MCF-7 was treated with a high dose of 2-NBDG (300 µM).42,43 in 
order to obtain an understanding of its uptake activity at varied concentrations of CsCl, NanoCs, 
and CP after a four-hour exposure. Cytochalasin B (CB), a known GLUT inhibitor.44 was used as 
a negative control for all 2-NBDG uptake investigations. The MCF-7 line was cultured in triplicate 
at a density of 12,000 cells per well in a 96 well plate. Before fluorescence analysis, cells were 
washed with dPBS and lysed with 50 µL of cell lysis buffer. A Synergy HT (Biotek, USA) plate 
reader, measured the fluorescent output (RFU) of each well’s contents with an excitation 
wavelength of 488 nm. The fluorescence intensity readings were processed as percentage ratios to 
the control (RFU sample/RFU control) and revealed that cells treated with the NanoCs and CB 
samples had fluorescent intensities at less than 80% for all concentrations above 125 µM, 
indicating that NanoCs is presumably restricting glucose uptake comparatively to CB (Figure 
2.27). Additional confirmation of glucose uptake inhibition through absorbance measurement of 
the sample at 480 nm was taken to confirm fluorescent results, and showed a similar pattern where 




Figure 2.27: RFU analysis of 2-NBDG uptake by MCF-7 cells at various concentrations of 





Figure 2.28: Absorbance graph of 2-NBDG loaded and lysed MCF-7 cells treated at various 





Flow cytometry of cells exposed to 2-NBDG can provide specific information on possible 
subpopulations affected by NanoCs exposure. Thus, MCF-7 cells were treated with 10 µM of 2-
NBDG as previously reported,42 prior to a four-hour incubation with 100 µM CB, CsCl, NanoCs 
at CsCl equivalence, and CP at volume equivalence to NanoCs at 37 °C. A Guava® EasyCyte Plus 
Flow Cytometer was used to count 5000 single cell events at an excitation of 488 nm for 2-NBDG 
fluorescence intensity readings. Since samples were being measured at the green emission 
wavelength of the flow cytometer, all samples were histogram subtracted from control values to 
eliminate any cellular autofluorescence signal. As previous data had suggested, CB exposure 
resulted in a highly effective suppression of 2-NBDG uptake, with NanoCs being the second most 
effective and followed closely by CsCl. CP and control samples showed high 2-NBDG uptake, 
with no apparent shift (Figure 2.29). To analyze how single-cell interactions with NanoCs may 
lead to inhibition of 2-NBDG uptake, confocal imaging, and single-cell fluorescent intensity 
analysis was performed on cellular samples treated in a similar fashion to the flow cytometry assay. 
Fixed and DAPI stained MCF-7 cells were excited at 488 nm for 2-NBDG fluorescence excitation. 
All images were corrected for cellular autofluorescence and analyzed for individual cellular 
intensity via ZEN Blue image processing software. Within control, CP, and CsCl samples it was 
evident that the 2-NBDG primary area of localization and accumulation was in the cytosol and not 
within cell nucleus or surrounding extracellular matrix. Additionally, each of these samples also 
showed evidence of high 2-NBDG localization within intracellular vesicles (Figure 2.30a-c). 
Nonetheless, NanoCs and CB samples both largely lacked signs of 2-NBDG accumulation and 
had no signs of vesicular entrapment within the cells (Figure 2.30d, e). Cells were measured for 
individual fluorescent intensities and averaged via ImageJ processing software, which reiterated 
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our hypothesis that NanoCs and CB had significantly decreased cellular 2-NBDG uptake with p 
values less than 0.001 (Figure 2.31).  
 
Figure 2.29: Flow cytometry RFU histogram of MCF-7 cells treated with respective samples. 
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Figure 2.30: Differential interference contrast microscopy images and confocal images of MCF-7 
cells treated with respective samples and then exposed to 10 µM 2-NBDG for four hours. Final 
image per row is an overlay including DAPI stain. White arrows indicate localized glucose storage 





Figure 2.31: Bar graph of average per cell pixel intensity of confocal 2-NBDG emission only as 
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Generation of Intracellular Reactive Oxygen Species in Response to Starvation 
Reactive oxygen species (ROS) are important molecules for identifying cellular stress due 
to their nature as products of mitochondrial starvation and signaling activators of autophagy-
related proteins (ATG) for programmed cell death (PCD).16 High concentrations of ROS within 
cells can also lead to increased oxidative damage of proteins with cysteine residues.16 One specific 
ROS target is the Na+/K+ symporter,18 which, if damaged, will further exacerbate the intracellular 
ion gradients and glucose import inhibition. Since Cs+ exposure showed evidence of reduced 
glucose uptake, we quantified cellular starvation via the production of intracellular ROS generated 
after NanoCs treatment. An ROS assay (Cell Biolabs Inc., San Diego, CA) on MCF-7 cells at a 
density of 12,000 cells per sample was performed using a known protocol that takes advantage of 
ROS oxidation on the cell-permeable dye 2’, 7’-Dichlorodihydrofluorescein diacetate (DCFH-
DA) to measure ROS content with 10 ppM sensitivity.45,46 Cells were pre-loaded with DCFH-DA, 
washed with dPBS, and then exposed to various concentrations of NanoCs as CsCl equivalence, 
and CP as volume equivalence to NanoCs, from 1000 to 31.25 µM in media for four hours. An 
ROS standard calibration curve was performed to calculate molar concentration of ROS within 
cell species and produced the curve Y = 9.87*X+1.077 (Figure 2.32). The DCFH-DA intensity 
values were subsequently translated to molar values and control values subtracted to eliminate 
noise from normal physiological ROS concentrations. The assay revealed that NanoCs did indeed 
initiate the production of a significant amount of ROS as compared to the CP sample which 
contained near physiological ROS concentrations (Figure 2.33). This suggests that the decreased 
glucose uptake caused by Cs+ exposure is driving high mitochondrial production of ROS, which 
in turn will lead to PCD. 
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Figure 2.32: ROS Standard curve in Log10 form for assessing actual ROS content within cells. 
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Figure 2.33: Graph depicting intracellular ROS content of 10k cells post four-hour exposure to 
respective samples at varying concentrations. Control values were subtracted from each data point 





Investigations of NanoCs Initiation of Apoptosis versus Cellular Death by Necrosis 
Since CsCl is known to be toxic at high doses as revealed by our MTT assay, we 
investigated the possibility that the NanoCs enabled delivery of Cs+ is causing a mutual initiation 
of apoptosis via cellular starvation, and ROS-activated autophagy, rather than general toxicity and 
induced cellular death via necrosis. To prove the possibilities, an Annexin V-FITC based apoptosis 
assay paired with propidium iodide (PI) and measured via Flow cytometry, unveiled cellular 
properties that indicate the mechanism of cell death. Annexin V is a non-cell permeable binding 
protein with high affinity for the lipid phosphatidylserine (PS) normally expressed on the inner 
leaflet of the cell membrane. However, cells have been shown to expose PS on the outer side of 
the membrane during early stages of apoptosis,47 which makes the fluoro-labeled Annexin V-FITC 
a perfect candidate for apoptotic cell tagging at early stages. PI is a well-documented fluorescent 
dye only permeable to dead cells. Thus, sole PI expression indicates necrotic cells only, while sole 
Annexin V-FITC expression indicates early stage apoptotic cells, and finally, dual expression 
indicates late stages of apoptosis. 
An apoptosis assay kit (eBioscience Inc, San Diego, CA) was performed on MCF-7 cells 
at a density of 100,000 cells per sample for a 48 hour 37 °C exposure of 100 µM CsCl, NanoCs as 
CsCl equivalence, and CP as volume equivalence to NanoCs. After the 48 hour incubation, cells 
were washed with dPBS and resuspended in 195 µL provided binding buffer, followed by exposure 
to 5 µL of Annexin V-FITC for PS binding. Cells were resuspended in fresh binding buffer and 
exposed to PI before processing via a Guava® EasyCyte Plus Flow Cytometer. Since FITC 
intensity was measured at the flow cytometers green spectral filter, all samples were histogram 
subtracted from control values to eliminate any cellular autofluorescent signal. A histogram 
analysis of FITC intensity among samples uncovered that both CsCl and NanoCs produced high-
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intensity readings, while NanoCs produced the highest counts of Annexin V-FITC binding (Figure 
2.34), indicating that NanoCs was a major influence in initiating apoptosis among cells. Further 
analysis and comparison to PI expression revealed that many cells exposed to NanoCs had a 
significant subpopulation that expressed higher amounts of Annexin V-FITC binding than 
expressed PI fluorescence. Thus, this subpopulation was in the beginning stages of apoptosis after 
48 hours of exposure, when compared to the control sample (Figure 2.35a, b).  
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Figure 2.35: Flow cytometry dot plot of (a) control cells and (b) NanoCs treated cells plotted as 





In Vivo Tumor Regression in a Xenografted Athymic Nude Mice Model 
While advanced 3D cell culture techniques can mimic some of the aspects of the in vivo 
tumor environment, these techniques are still lacking in the complexity found in vivo.  In addition 
to tumor architecture, the global setting of the tumor in the animal cannot be replicated yet with 
cell culture techniques. Thus, after optimizing treatment strategies in vitro, it had to be established 
in animal models to get a real picture of treatment efficiency. Thus, to evaluate the efficacy of our 
Cs+ loaded nanoparticle system for anti-cancer properties, tumor regression efficiency experiments 
were performed in vivo (Figure 2.36). Nude mice were subcutaneously injected with MCF-7 cells 
to develop tumors of 5mm x 5mm size before starting the intratumoral injections with various 
treatments.  Grown tumors were injected with 40 µL of CsCl solution and NanoCs suspension with 
3.0 mM cesium concentration, as well as 40 µL of CP. Injections and tumor size tracking were 
followed using a caliper through on the 14, 18, 22 and 26th day of tumor growth, while further size 
tracking continued for an additional 9 days. Animals were allowed to feed on food and water with 
no specific control. At the end of the experiment, average tumor sizes were found to be 250, 150 
and 125 mm3 in animals treated with CP, CsCl, and NanoCs, respectively. These changes in final 
tumor volumes were of critical importance based on their treatment type and significance. The 
significance of these changes was proven bio-statistically by ONE WAY ANNOVA performed on 
various tumor sizes at different time points. It revealed a value for p = 0.0546 between tumor sizes 
for CP and NanoCs treated animals (Figure 2.37a-d, Figure 2.38). To verify the mechanism of 
tumor regression, an H&E staining protocol was performed by following standard method supplied 
by core facility IGB. It showed presence of an apoptotic population with fragmented nuclei of 
tumors treated with CsCl and NanoCs formulation. The presence of vacuoles (white areas) in tissue 
sections from tumors, which were treated with CsCl (Figure 2.39b) and NanoCs (Figure 2.39c), 
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indicated the cell starvation.48 This result further strengthens the chances of assuming that probably 
Cs inducing apoptosis via cellular starvation. It will be a matter of further investigation in future 
studies. Thus, in vivo study clearly supported the in vitro observation of cancer cell growth 
inhibition via apoptosis induction in terms of decreased tumor size and presence of fragmented 
nuclei in the apoptotic cell population. It verified the role of NanoCs as an effective anticancer 
nanomedicine with success in tumor regression in a rodent model. To the best of our knowledge, 
this is the first report to study the nano-enabled delivery of cesium. Although more detailed in vivo 
studies are warranted, we anticipate this early investigation will trigger a further exploration of 
cesium as a therapeutic agent. 
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Figure 2.36: In vivo tumor regression analysis post NanoCs injections in xenograft mouse model. 





Figure 2.37: Timeline of experimental procedures performed on animals and tumors treated with 
(a) CP; (b) CsCl; (c) NanoCs and (d) tumor volume after excision post euthanasia from animals 
treated with (d2) CP; (d3) CsCl and (d4) NanoCs on cm scale (d1). 
 
Figure 2.38: Tumor volume regression analysis for all the animals treated with various used 
formulations. ONE-WAY ANOVA was performed on tumor sizes and found as p = 0.0546 
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Figure 2.39: H&E stained tumor sections after microtomy on waxed tumors from animals treated 
with (a) CP, (b) CsCl and (c) NanoCs.  Arrows show the location of the apoptotic cell population 






Within this study, we have investigated the highly theorized concept of “high pH therapy” 
lead by CsCl supplementation, as well as other possible mechanisms initiated via in vitro and in 
vivo CsCl delivery. For a detailed scientific understanding of cesium delivery, we used proper 
scientific procedures and analysis on a model breast cancer cell line to resemble tumor treatment. 
For the first time, we have identified a facile and amenable procedure for the synthesis of cesium-
based nanoparticles for efficient delivery of cesium ion to cancer cells as compared to a free CsCl 
salt solution. Our data indicates that although CsCl has the ability to decrease hydrogen ion activity 
for an observed pH raise of an acidic non-buffered solution, the amount necessary to initiate 
programmed cell death is far out of reach. Intracellular delivery of Cs+, via the optimized nano-
delivery vehicle: NanoCs, still did not cause a pH change as previously expected and no high pH 
initiated cell death was observed. Furthermore, alternative hypothesized mechanisms have been 
identified as different forms of CsCl mediated cell death than previously expected. Our data 
suggests that Cs+ internalization via NanoCs limits glucose internalization. Additionally, this 
consequential cellular starvation leads to the mitochondrial generation of ROS, an autophagy 
activator and precursor to PCD. A further investigation into the hypothesized method of cell death 
using a popular flow cytometry analysis method revealed that Cs+ delivery via NanoCs, indeed 
causes high rates of cellular initiated apoptosis rather than death by toxicity induced necrosis. In 
vivo studies showed that xenograft tumors grown in nude mice regressed to a statistically 
significant level after intra-tumoral injection of NanoCs. H&E analysis of tumor sections 
characterizes with apoptotic cell population with fragmented nuclei. Further investigations into the 
exact mechanism of Cs+ induced membrane potential disruption and inhibition of ion dependent 
glucose co-transporters is essential for translation into clinical settings. Additionally, studies 
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regarding the NanoCs long term effects and biodistribution properties in vivo are vital for 
validation of the system. 
Methods 
Unless stated otherwise, all material and reagents were purchased from Sigma–Aldrich, St. 
Louis, MO, and were used without further purification. Solvents were used as received and without 
further purification. 
NanoCs and CP Synthesis 
Polyethylene glycol cetyl ether (2 mg) was melted at 65 °C for 5 min followed by the 
dropwise addition of 2 ml of water (approximately 1 drop/sec) (for NanoCs, 2 ml of 50 mg/ml 
CsCl in water was added dropwise). The solution was allowed to stir for 20 min at 1150 rpm. 
Simultaneously, a solution of poly(styrene)67-block-poly(acrylic acid)27 (PS67-b-PAA27, Mn 
1,600–1,950 (poly(acrylic acid)), Mn 6,500–7,000 (polystyrene), Mn 8,100–9,100, average Mn 
8,700, mp: 192–197 °C; Mw/Mn = 1.2) was prepared by adding 2 mg of the amphiphilic polymer 
dissolved in 0.5 ml of tetrahydrofuran (THF) to a glass vial. After the polyethylene glycol cetyl 
ether micellar suspension was stirred for 20 min, 500 μL of PS67-b-PAA27/THF solution was added 
drop-wise (approximately 1 drop/10 sec) to the solution. The solution was left stirring overnight 
to allow THF evaporation. At the end of the procedure, volume was increased up to 2 ml with 
autoclaved nanopure water (0.2 μM). The suspension was further stirred for 10 minutes. Finally, 
the suspension was stored at 4 °C overnight to cure the core of the particle. The NanoCs were 
purified by dialysis against nanopure (0.2 μM) water using a 10,000 Da MWCO cellulose 
membrane for a prolonged period of time to release free CsCl ions from the nanoparticle solution 
(CP was also dialyzed for consistent preparation). Furthermore, nanoparticles were passed through 
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a 0.45 μm Acrodisc Syringe filter. Nanoparticles were stored under argon atmosphere at 4 °C in 
order to prevent bacterial growth. 
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) 
ICP-OES was performed on NanoCs particles, post dialysis, to measure cesium content 
entrapped within polymer solution with a Perkinelmer 2000DV ICP-OES (Noyes Microanalysis 
Laboratory, UIUC). For the cesium release study, NanoCs post routine dialysis was further 
dialyzed in Nano pure H2O (18MΩ) at room temperature. Various samples were extracted from 
inside the dialysis cassette and measured via ICP-OES for cesium concentration. 
Calculating the Amount of Cs+ per Nanoparticle 
Johansson et al.49 reports that poly ethylene glycol cetyl ether (PEGCE, Average Mn 1124) 





















Dynamic Light Scattering Measurements 
Hydrodynamic diameters were determined using a Malvern Zetasizer ZS90 particle size 
analyzer, while scattered light was collected at a fixed angle of 90°. A photomultiplier aperture of 
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400 µm was used with the incident laser power adjusted to obtain a photon counting rate between 
200 and 300 kcps. Diameter values depended on measurements whereupon the measured and 
calculated baselines of the intensity autocorrelation function had to agree within +0.1%. All 
determinations were made in multiples of three consecutive measurements at 15 runs each. 
Determination of Surface Zeta Potential 
Zeta potential (ζ) values for NanoCS and CP were determined with a nano series Malvern 
Zetasizer zeta potential analyzer (Fredrick Seitz Material Research Laboratory, University of 
Illinois at Urbana Champaign, (MRL facility, UIUC)). Data were acquired in the phase analysis 
light scattering (PALS) mode following solution equilibration at 25 °C when calculation of ζ from 
the measured electrophoretic mobility (μ) employed the Smoluchowski equation (Equation 2.4), 
which is expressed as:  
Equation 2.4 μ = εζ/η 
where ε and η are the dielectric constant and the absolute viscosity of the medium, respectively. 
Measurements of ζ were reproducible to within ± 6 mV of the mean value given by three 
determinations of 15 data accumulations. 
Transmission Electron Microscopy Measurements 
Two µL of particle suspension was applied to carbon coated TEM grids. Grids were then 
blotted, air dried, and imaged on a JEOL 2100 Cryo TEM machine via a Gatan UltraScan 2k × 2k 





Atomic Force Microscopy 
A Digital Instruments Dimension 3000 series AFM (MRL facility, UIUC) was used for 
scanning the samples using standard Veeco tapping mode silicon probes with a platinum–iridium 
(PtIr) coating. In a typical experiment, suspended NanoCS or CP samples were dried in a 
desiccator on freshly cleaved mica. Dried samples were placed on the AFM platform and scanned. 
Pertinent scanning parameters were fixed as follows: Example of tip velocity: 4 m/s for 2 m, 15 
m/s for 5 m, 30 m/s for 10 m; resonant frequency (probe): 60–80 kHz. Aspect ratio: 1:1; resolution: 
512 samples/line, 256 lines.  
EDX Analysis 
Energy dispersive X-ray (EDX) spectrum analysis was performed to demonstrate the 
presence of cesium with nanoparticles in addition to carbon and oxygen found in particle 
preparations. Samples were prepared on metal stubs decorated with silicon block. Suspension of 
particles were drop cast on carbon tape and allowed to air-dry before vacuum desiccation for 5 hrs. 
EDX was carried out on an ISIS EDS X-ray Microanalysis System, Oxford Instruments (MRL 
facility, UIUC). 
Raman and FTIR Spectroscopy 
All Raman measurements were taken on a Nanophoton Raman instrument (MRL facility, 
UIUC) with a 532 nm wavelength laser for one min at 0.2% laser power using a 20x objective. For 
each spectrum a grating (600 l mm-1) scan was taken over the range of 120–2700 cm-1. An average 
of 20 spectra were recorded and averaged per sample.  
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For Fourier Transform Infrared (FTIR) analysis, aqueous suspensions of particles were 
drop cast onto MirrIR IR-reflective glass slides (Kevley Technologies, Chesterland, Ohio, USA) 
for measurements using a Nicolet Nexus 670 FTIR (MRL facility, UIUC). For each measurement 
100 × 100 μm images were collected at 1 cm−1 spectral resolution with 64 scans per pixel and a 
25 × 25 μm pixel size and individual spectra were corrected for atmospheric contributions.  
MTT Assay 
The cytotoxic effect of CP and those of NanoCs were investigated with a 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich, MO, 
USA). An MCF-7 human estrogen receptor positive breast cancer cell line was plated on a 96-well 
plate at a density of 10,000 cells per well (Greiner Cellstar® 96 well plates, Sigma-Aldrich, MO, 
USA) and exposed to CP and NanoCs after 24 hr at 37 °C. Followed by a 48 hr exposure time, 
20 μL (5 mg/mL) of MTT solution was added to each well and cells were further incubated for 
another 4 hours. After exposure, media was aspirated and 200 μL of dimethyl sulfoxide (DMSO, 
≥99%, MP Biomedicals, USA) was added to dissolve formazan crystals. Optical density of 
samples was determined by Synergy HT (BioTek, USA) with a reference wavelength of 570 nm. 
Percentage cell viability was determined by the following equation (Equation 2.5): 





For inhibitor studies, MCF-7 cells were plated on a 96-well plate in triplicate at a density 
of 10,000 cells per well (Greiner Cellstar® 96 well plates, Sigma-Aldrich, MO, USA) and exposed 
to each inhibitor for one hour. Inhibitor concentrations are as follows; 28 µM chlorpromazine, 80 
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µM Dynasore, 180 nM Nystatin, 10 µM NaN3 and 50 µM DOG. Cells were then washed and 
incubated with a 100 µM NanoCs equivalent of CsCl. The cytotoxic effects of the NanoCs particles 
were measured using the same methods as the MTT reduction assay. 
Confocal Microscopy 
SNARF and NBDG cell internalization measurements were carried out using a Zeiss 710 
confocal scanner. For all samples, the MCF-7 cell line was plated on poly-L-lysine coated circular 
coverslips at a cell density of 400,000 cells per 25 mm coverslip. After 24 hours, cells were treated 
with respective components and fixed using 8% paraformaldehyde. Cells were then stained with 
DAPI containing Vectashield mounting medium prior to imaging. In both experiments, the sample 
was excited at 405 nm and the emission was measured at 461 nm using suitable filters to locate 
and image cell nuclei. 
Cellular pH Change Using SNARF 
Cells were treated with 0.5 µg of 5-(and-6) Carboxy SNARF®-1 AM 24 hours post plating 
and incubated at 37 °C for 30 minutes. After dye loading, cells were washed with dPBS and treated 
with respective samples with an incubation time of 4 hours. Cells were then washed with dPBS 
and fixed for confocal imaging as described above. For SNARF imaging and analysis, samples 
were excited at 488 and imaged at 535 nm and 640 nm gates to visualize dye intensity 






NBDG Glucose Uptake 
For 96 well plate reading of 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-
glucose (NBDG) (Cayman Chemicals, Michigan USA), MCF-7 Cells were plated at a cell density 
of 12,000 cells per well. 24 hours after plating, cells were treated with respective samples at 
varying concentrations and incubated at 37 °C for 30 min. Cells were subsequently treated with 
300 µM of NBDG and incubated at 37 °C for an additional 3.5 hours. After treatment, cells were 
washed with dPBS and lysed in 50 µL lysis buffer. The fluorescence spectra of each well were 
measured with a Synergy HT (BioTek, USA) Plate reader at 488 excitation and 535 emission. 
Each respective well was additionally measured for absorption at 480 nm.  
Flow Cytometry samples were performed on cells (cell density: 500 cells/µL) treated with 
10 µM NBDG on a Guava® EasyCyte Plus Flow Cytometer. For each sample data from 5000 
single cell events were collected within 1 minute at an excitation of 488 nm. 
Confocal samples were also treated in a similar fashion as mentioned above with 10 µM 
NBDG treatment and fixed similarly to SNARF samples. NBDG exposed cells were imaged at 
488 excitation and 535 emission. 
Intracellular Reactive Oxygen Species Assay (ROS) 
ROS Assay was purchased from Cell Biolabs Inc., San Diego, CA. MCF-7 was plated on 
a 96 well plate at a cell density of 10,000 cells per well for 24 hours. Cells were then washed with 
dPBS and treated with 1mM DCFH-DA in media at 37 °C for 60 minutes. Cells were then washed 
with dPBS and treated with respective samples at varying concentrations for 4 hours at 37 °C. 
Cells were then re-washed with dPBS, lysed with lysis buffer and incubated at room temperature 
for 5 minutes. The fluorescence was then read by a Synergy HT (BioTek, USA) plate reader at 
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488 excitation and 535 emission. A standard was created to correlate the molarity of ROS found 
in cell samples. 
Apoptosis Detection Assay 
Apoptosis detection kit was purchased from eBioscience Inc, San Diego, CA. MCF-7 cells 
were plated in a 24 well plate at a cell density of 100,000 cells per well for 24 hours. Cells were 
then treated with respective samples at varying concentrations and incubated at 37 °C for an 
additional 24 hours. Cells were then washed with dPBS and suspended in binding buffer with 5 
µL of Annexin V-FITC and allowed to incubate at room temperature for 10 minutes. Cells were 
washed with and resuspended in binding buffer for treatment of Propidium Iodide (20 µg/ml). 
Samples were then analyzed via a Guava® EasyCyte Plus Flow Cytometer. For each sample, data 
from 2000 single cell events were collected within 1 minute at an excitation of 488 nm. 
Animal Studies 
To evaluate the efficacy of adopted strategy of loading Cs in nanoparticle system animal 
experiments were performed on the least amount of animals necessary for significant results. The 
experimental protocol was approved by the Institutional Animal Care and Use Committee 
(IACUC), University of Illinois, Urbana–Champaign, and satisfied all University and National 
Institutes of Health (NIH) rules for the humane use of laboratory animals. All the animal 
experiments were carried out in accordance with the approved guidelines. Athymic mice were 
bought from Charles River Laboratories International, Inc. USA. Upon arrival, athymic mice are 
allowed 1 week for acclimation. Animals were single-cage housed and had free access to food and 
water. Animals were housed in Integrative Genomic Biology, University of Illinois at Urbana-
Champaign. Animals were anesthetized with isoflurane before injecting the 5 x 106 MCF-7 cells 
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suspended in matrigel (50%, v/v) using a Hamilton auto-injector or standard syringe tipped with a 
26 gauge 1/2" long needle.  Mice were monitored during recovery from the anesthesia in a clean 
cage.  
Mice were monitored daily for signs of discomfort and behavioral change. The mice’s body 
weight was measured every week. Criteria for interventions were set up as animal body weight 
drops by 20% or tumor increase to 17 x 17 mm2. Tumor size was determined by measuring the 
length and width of the tumor and then calculating the tumor volume via the formula 





Intra-Tumoral Injections and Tumor Regression Analysis 
Animals were followed till tumors grew to a minimum of 5 x 5 mm2 before starting the 
treatment protocol. Isoflurane-oxygen mixture was used to anesthetize the animals with 3-4% 
isoflurane gas from a vaporizer and constant anesthesia maintained with 1-2% isoflurane via an 
inlet tube. A second tube was used to remove carbon dioxide and excess anesthetic. All the 
personnel involved wore protective lab coats, face masks, sterile gloves during experimental 
procedures. A total of 40 µL particle suspensions were injected to each tumor on every 4th day till 
26th day while following the tumor size growth and regression for the next 9 days. At the end of 
experiment, animals were euthanized, tumors collected and stored in tissue cassettes dipped in 
10% formalin before performing the tissue fixation protocol in Leica ASP300 tissue processor. 
Embedded tumor blocks were clamped in microtome (Leica) and sectioned at 7 μm thickness. 
Paraffin-embedded sections (7 μm) were subjected to hematoxylin and eosin (H&E) staining. H&E 
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staining was performed by following standard protocol supplied by core facility IGB. In brief, 
sections were processed by deparaffinize sections, in xylene, absolute alcohol, 95% alcohol and 
70% alcohol before staining in mayer hematoxylin solution and counterstaining in eosin Y 
solution. Mounted the section in xylene based mounting medium. The morphological changes of 
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 CHAPTER 3: COMBINATORIAL NANOENCAPSULATION OF SILVER IONS 





Bacterial-based infectious diseases continue to worsen as instances of antibiotic resistance 
rise. Research into silver-based or drug-based approaches shows promise, but their clinical 
translation is hindered by their low incremental effectiveness over currently used treatments. To 
address these issues, a combinatorial approach using both silver and a fluoroquinolone drug could 
provide a more suitable substitute for current techniques. For a truly synergistic treatment, 
however, the packaging and delivery of these agents must be chosen strategically. Here, we 
investigate a nano-level approach by packaging ionic silver within inverted micelle capsules and 
subsequently wrapping these capsules with a lipid shell composed of a synthesized levofloxacin 
prodrug. Our procedure yielded 192 ± 31 nm particles, which we termed the AI-Pro-NP. During 
bacterial tests, the combination of silver ions and the levofloxacin prodrug had an enhanced and 
additive antimicrobial effect over each constituent alone. Furthermore, the AI-Pro-NP showed 
evidence of disrupting vital cell structures as imaged by transmission electron microscopy of 
bacteria and measured by gel electrophoresis of extracted DNA and proteins. Finally, a live/dead 
cell assay confirmed the combinatorial effects of the AI-Pro-NP and its ability to serve as an 
integral antibiotic. 






With the wealth of antibacterial agents in clinical use, instances of antibiotic resistance 
continue to rise and are becoming a growing concern for the future of infectious disease treatments. 
Both gram-positive and gram-negative bacteria have become resistant to various antibiotics such 
as macrolides1 and quinolones.2 The need to design and develop new agents and methods of 
delivery with potent antimicrobial activity is urgent. 
Fluoroquinolones, a derivative of quinolones with a C-6 fluorinated and a C-7 piperazine 
ring residue, have had major successes across gram-positive and gram-negative bacteria.3 Yet, not 
even these antimicrobial agents are immune to resistance.4 Therefore, independent investigations 
have expanded the fluoroquinolone family by developing multiple sub-derivatives to diversify 
their antimicrobial mechanism. For example, the chemically versatile piperazine ring enabled 
facile modification of levofloxacin, a topoisomerase inhibitor with significant anti-gram-positive 
activity,5 which resulted in the synthesis of countless derivative structures.6,7 One particular 
fluoroquinolone derivative of interest is prulifloxacin modified to a lipid tail for prodrug 
functionality, which is a method that has rapidly gained popularity for drug delivery.8,9 This 
prulifloxacin prodrug was found to have a greater potency towards the gram-negative bacteria E. 
coli, and an ofloxacin-resistant strain of Enterobacter cloacae than the unmodified form.10  
Another efficient and popularized method for combatting bacterial infections is the use of 
silver-based platforms. For example, Panacek et al. synthesized 25 nm silver nanoparticles that 
exhibited high antibacterial and bactericidal activity against both gram-positive and gram-negative 
bacteria, including multi-resistant strains.11 Furthermore, Jung et al. have shown that solutions of 




Staphylococcus aureus12 due to the silver ions’ high affinity for thiol groups on essential 
biomolecules, such as the amino acid, cysteine.13 
Here we introduce a unique combinatorial strategy for enhanced antibiotic treatment. We 
developed a nanocapsule derived from inverted micelle packaging and a levofloxacin-prodrug 
lipid wrapping for delivering ionic silver, termed the AI-Pro-NP. Our motivation for this design is 
to simultaneously disrupt the bacterial cell wall and other cellular mechanisms, while delivering 
levofloxacin intracellularly. With our research methodologies, we found that this nanocapsule is 
robust, and its antibiotic activity is quantifiably superior to either silver (Ag+) ions or the 
levofloxacin prodrug alone. Furthermore, DNA gel assays showed that the AI-Pro-NP disrupted 
vital cell structures at the molecular level. Finally, transmission electron microscopy (TEM) and 
in vitro imaging of AI-Pro-NP treatments provided visual evidence of their antibiotic activity at 
the cellular level. Altogether, the AI-Pro-NP technique shows that a multi-mechanistic approach 
is a superior measure for infectious disease therapy. 
Results and Discussion 
Nanoparticle Synthesis 
At the inception of the AI-Pro-NP synthesis, a solution of 600 mM AgNO3 was vigorously 
shaken in equal parts volume with 50 mM dodecanoic acid (C12H24O2) solubilized in anhydrous 
chloroform. The two layers were allowed to settle for a prolonged period before the aqueous layer 
was extracted. Dodecanoic acid was chosen as the optimal inverted micelle constituent since the 
electrostatic interactions between the positive Ag+ ions and the negatively charged carboxylic acid 
groups would lead to a higher degree of encapsulation. To analyze the transfer capability of Ag+ 




plasma optical emission spectrometry (ICP-OES) on the transfer of aqueous AgNO3 (600 mM) to 
an anhydrous chloroform layer with or without dodecanoic acid (50 mM). Measurements of the 
control sample (absent of dodecanoic acid) revealed that 7.2 ± 0.6 mM Ag+ inevitably transferred 
to chloroform layer due to a reduced integrity of the chloroform’s anhydrous state after contact 
with H2O. Nonetheless, vigorous shaking of aqueous AgNO3 with the dodecanoic acid solubilized 
in the chloroform layer, initiated the transfer of 22.0 ± 2.2 mM Ag+ ions into self-assembled 
dodecanoic acid inverted micelles (Figure 3.1). 
After the Ag+ ions have been encapsulated by the reverse micelles within the organic 
chloroform layer, they were mixed with a lipid cocktail consisting of phosphatidylcholine (PC), 
1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (PE), and cholesterol at an optimized mM 
ratio of 3:0.23:0.03:0.03 of dodecanoic acid:PC:PE:cholesterol. The organic layer was then 
evaporated to form a thin film, which was flushed with nanopure water (18 MΩ, pH 7.4) and 
subjected to probe sonication to produce nanoparticles with a final mass concentration of 0.81 
mg/ml (Figure 3.2). For naming conventions, this non-prodrug, lipid-wrapped inverted micelle 
capsule carrying Ag+ ions is termed the Ag Ion Nanoparticle (AI-NP). From the encapsulation 




Figure 3.1: Histogram comparing the mM of silver transferred from aqueous AgNO3 to chloroform 


























To ensure nanoparticle formation and size consistency, we performed dynamic light 
scattering measurements, which revealed the AI-NPs’ average hydrodynamic diameter to be 192 
± 31 nm with a polydispersity index (PDI) of 0.2 ± 0.1 (Figure 3.3). Moreover, a one-week stability 
analysis of the AI-NPs stored in the dark at 4 °C showed consistent hydrodynamic diameter 
integrity, indicating that these particles are suitable for multi-day storage (Figure 3.4). 
Transmission electron micrographs of AI-NPs supported the nanoparticle formation and the 
presence of encapsulated silver (Figure 3.5). Within these micrographs, the encapsulated Ag+ was 
visually contrasted against the outer nanoparticle material which is explained by the silver’s higher 
electron density (Z = 47).  
To measure the AI-NPs’ silver release profile, we dialyzed the nanoparticles with 10,000 
molecular weight cut off (MWCO) cassettes against nanopure water (18 MΩ, 7.4 pH) at room 
temperature (25 ○C). The nanoparticles were compared to an AgNO3 solution of an equivalent 
concentration. Over the course of 48 hours, the AI-NP sample maintained 60.9% of its original 
Ag+ ion concentration, while the AgNO3 sample lost the majority of its silver content in the first 
hour (Figure 3.6). This observation demonstrates the AI-NPs’ robust ability to encapsulate and 
hold their contents without compromising their potency as a silver delivery vehicle. 
As discussed above, both fluoroquinolone drugs and silver have excellent bactericidal 
properties stemming from their ability to disrupt different, yet key mechanisms in bacteria needed 
for bacterial survival. Therefore, we aimed to combine the topoisomerase inhibitor, levofloxacin, 
with the silver’s capability of physically disrupting cell walls, DNA, and Protein. We thus modified 





Figure 3.3: Histogram representing the number averaged (%) of AI-NPs. 
 
  

























Figure 3.4: A 7-day shelf life stability assessment of the nanoparticle’s Hydrodynamic diameter 
(stored at 4° C). 
  
















Figure 3.5: TEM micrograph to visualize nanoparticle morphology; Ag+ inverted micelle capsule 





Figure 3.6: Ag+ release profile against a 10k MWCO dialysis cassette, and measured by ICP. 
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The levofloxacin prodrug synthesis began with Lyso-PC (>99%), Levofloxacin (≥98.0%), 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), and 4-
dimethylaminopyridine, incubated and stirred at room temperature in chloroform for three days 
(Figure 3.7). The formation of prodrug was confirmed by Electrospray ionization mass 
spectrometry (Figure 3.8) 1H –NMR (Figure 3.9), and FTIR (Figure 3.10), spectroscopies results. 
The peak at m/z value of 839.4715 was identified, indicating the formation of prodrug. 
The levofloxacin prodrug was then combined with the AI-NP by replacing the PC lipid 
molecule and creating the combinatorial nanoparticle termed AI-Pro-NP. This was carried out with 
the new lipid cocktail consisting of an optimized mM ratio of 3:0.57:0.03:0.03 of dodecanoic 
acid:prodrug:PE:cholesterol. 
To expand the characterization of the AI-Pro-NPs, we investigated the nanoparticles’ 
stability and robustness for in vito applications requiring bacterial treatment, through zeta potential 
measurements and tracking of their hydrodynamic diameter within bacterial media. Zeta 
measurements of control particles (made of the lipid cocktail with no Ag+ or prodrug), AI-NPs, 
and AI-Pro-NPs remained at 9 ± 2 mV, 9 ± 2 mV, and 9 ± 0 mV, respectively, indicating that the 
encapsulated contents and the levofloxacin surface modification did not significantly change the 
stability profile of the AI-Pro-NP nanoarchitecture. When the nanoparticles were kept in Brain 
Heart Infusion Broth (BHI) at 37 °C over the course of one week, we observed slight variations 
but no significant increases in their hydrodynamic diameter. This points to aggregation of the 
nanoparticles’ protein corona rather than the aggregation of nanoparticles themselves due to 
instability (Figure 3.11). Such a result was expected since the zeta potential of each nanoparticle 




Figure 3.7: Schematic showing the prodrug synthesis procedure. The final chemical structure is 





Figure 3.8: Electrospray ionization mass spectrometry of levofloxacin prodrug (C42H69FN4O10P+). 











Figure 3.10: FTIR spectral analysis of each levofloxacin prodrug constituent paired with its near 






Figure 3.11: Seven-day stability assessment of each nanoparticle’s hydrodynamic diameter in BHI 
media. 
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To compare the AI-Pro-NPs’ antimicrobial effects to each of its separate constituents, we 
tested the LD50 level of each nanoparticle variation at a 10% v/v treatment with the bacterium 
Bacillus subtilis (ATCC 6633). This species was chosen because of its history as an exceptional 
bacterial model for studying resiliency against anti-microbial agents,14,15 as well as its ability to 
secrete large amounts of industrially important enzymes to cleave the prodrug ester bond.16 By 
tracking the optical density of B. subtilis in BHI media at 546 nm over several time points, we 
gathered that the combinatorial effect of Ag+ ions and the levofloxacin prodrug led to an additive 
toxic effect, with the combinatorial approach making the most significant impact (Figure 3.12). 
Specifically, the AI-Pro-NPs reached the LD50 level at 1.3 h, while the AI-NP and the levofloxacin 
prodrug reached the LD50 at 2 h and 4.5 h, respectively. 
Although we showed that the levofloxacin prodrug works as an effective topoisomerase 
inhibitor, the purpose of combining levofloxacin with Ag+ is to simultaneously disrupt the bacterial 
cell wall and other critically important cellular mechanisms, in parallel with delivering 
levofloxacin intracellularly. To investigate this disruptive process, we extracted DNA from treated 
bacterial samples and performed gel electrophoresis to visualize the effects of Ag+ ions at the 
molecular level. For DNA samples, the control particle (CP) and levofloxacin prodrug produced 
similar results as the control; this is expected because neither CP nor the prodrug are physically 
destroying cellular mechanisms. As for the AI-NP-treated and AI-Pro-NP-treated samples, DNA 
bands disappeared from the electrophoresis gels (Figure 3.13). This interesting phenomenon can 
be explained by the Ag+ ions breaking the DNA into pieces small enough to run off the gel. Another 




macromolecular silver structures that are too large to migrate through the gel and thus remain 
confined to the gel well.  
To examine the disruptive capabilities of Ag+ ions at the cellular level, we investigated 
bacterial cells with TEM. While control samples looked healthy in TEM micrographs (Figure 
3.14), the micrographs of the AI-Pro-NP-treated bacterial samples show cross-sections of bacteria 
with compromised cell walls emptied of bacterial cytoplasm (Figure 3.15). In many of these 
micrographs, the AI-Pro-NPs can be seen inside disrupted cells, which provides evidence that the 
damage was due to Ag+ ions. 
Finally, to visualize the effectiveness of the combinatorial AI-Pro-NPs against B. subtilis, 
we assessed the treated bacteria with a live/dead confocal assay. For control and CP samples, cells 
remained intact and expressed green fluorescence (Figure 3.16a, b), indicating healthy unaffected 
cellular functions. Contrarily, cells exposed to the levofloxacin prodrug showed low viability yet 
remained intact, as evidenced by a high population of cells expressing red fluorescence (Figure 
3.16c). Finally, both AI-NP-treated and AI-Pro-NP-treated cells had damaged cellular anatomies, 
with a combination of red and green fluorescence, which resulted in a yellow/orange expression 
(Figure 3.16d, e). This yellow/orange expression can be explained by the compromised cell wall, 
which does not have selectivity towards either dye. Even more so, the AI-Pro-NP-treated samples 
showed very little evidence of any live or intact cells as compared to AI-NP-treated samples alone. 
This bolstered our assessment that a combinatorial approach with our novel nanoarchitecture leads 




Figure 3.12: Percent change in B. subtilis viability after treatment with each sample. 
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Figure 3.13: Fluorescence image of an agarose gel with DNA samples of bacteria treated with each 
nanoparticle variation. Order of wells from the left: 1) DNA Ladder, 2) positive control 3) negative 





Figure 3.14: TEM micrograph of bacterial cells treated with CP. Inset is added from other imaging 
samples to show reproducibility. White artifacts in the center of cells are consequence of slicing 





Figure 3.15: TEM micrograph of bacterial cells treated with AI-Pro-NP. Inset is added from other 
imaging samples to show reproducibility. White artifacts in the center of cells are consequence of 
slicing samples at 60 nm thin. Blue arrows indicate AI-Pro-NP, while purple arrows point to 





Figure 3.16: Cellular samples stained with either SYTO 9 (green) or propidium iodide (red). Each 






In conclusion, we have demonstrated a combinatorial approach which uses the destructive 
properties of Ag+ combined with a prodrug derivative of the popular antibiotic, levofloxacin, for 
bactericidal applications. This combined approach is strengthened by the novel nano-based 
packaging and delivery system, which uses inverted micelle self-assembly and lipid wrapping to 
ensure both Ag+ ions and levofloxacin are jointly delivered to bacteria at the cellular level. We 
thoroughly characterized these nanoparticles and measured their bactericidal effectiveness in 
multiple experimental mediums. Thorough quantification showed that the combinatorial effects of 
Ag+ ions and the levofloxacin prodrug in the AI-Pro-NPs are additive and yield a higher toxic 
effect than each constituent alone. After analyzing the integrity of the bacterial DNA and proteins, 
we showed that the AI-Pro-NPs exhibited further antibacterial destructive effects at the molecular 
level. Furthermore, we visualized the effective antibacterial properties of Ag+ delivered by the AI-
NPs with bacterial TEM, which confirmed the bacterial cell wall was, in fact, compromised. 
Finally, live/dead assays confirmed that the combinatorial AI-Pro-NPs had a powerful antibacterial 
outcome as compared to Ag+ ions or the prodrug alone. 
Moving forward, additional investigations are warranted for future applications with the 
AI-Pro-NPs or similar combinatorial techniques. For example, this nanoarchitecture can be used 
to entrap material other than ionic silver, such as biological matter or other molecular compounds. 
Additionally, the adaptability of AI-Pro-NPs to other in vivo antibiotic applications should be 
investigated to upgrade this novel delivery platform towards a multifunctional, all-purpose 






Unless stated otherwise, all material and reagents were purchased from Sigma–Aldrich, St. 
Louis, MO, and were used without further purification. Solvents were used as received and without 
further purification. 
Inverted Micelle Transfer 
An equal volume ratio of 50 mM of dodecanoic acid dissolved in chloroform and an 
aqueous suspension of 600 mM silver nitrate (AgNO3) was added into a 1-dram (3.7 ml) vial and 
vigorously shaken for several seconds to homogenously mix the layers. The vials were then 
allowed to separate and settle for a prolonged period of time. At this point, the organic layer 
became cloudy indicating the successful transfer and encapsulation of the silver ion.  
Nanocapsule Formation 
The inverted micelle and silver ion composite (while suspended in chloroform), was added 
to a glass bulb along with a lipid cocktail. For control samples, this lipid cocktail consisted of 
phosphatidylcholine (PC, Coatsome, NOF Corporation, Tokyo, Japan) 1,2-Dioleoyl-sn-glycero-3-
phosphatidylethanolamine (PE, Cayman Chemical Company, MI, USA), and cholesterol at an 
optimized mM ratio of 3 : 0.23 : 0.03 : 0.03 of dodecanoic acid:PC:PE:cholesterol. For samples 
requiring the Levofloxacin Prodrug (NP-Pro or Ag-Pro samples), the lipid cocktail consisted of 
the Levofloxacin/Lyso-PC derived prodrug (Molecular weight 839.4715 g/mol) at an optimized 
mM ratio of 3 : 0.57 : 0.03 : 0.03 of dodecanoic acid:Prodrug:PE:cholesterol. 
The chloroform in the glass bulb was evaporated by a rotary evaporator (RE200, Yamato 




sample was then placed in a desiccator (Labconco, Kansas City, MO, USA) for 30 minutes. Water 
(pH 7.4, 18 MΩ Millipore H20) was added to the bulb at a volume to produce a final concentration 
of 0.8 mg/ml. The sample was subject to probe sonication for 30 seconds (Amp: 1, On: 2 sec, Off: 
2 sec). The samples were then immediately placed in an ice-bath and incubated for one hour at 4 
°C. Following incubation, the samples were filtered through a 0.22 μm PTFE syringe filter and 
dialyzed against a 10,000 molecular weight cut off cassette (Thermo Scientific Product # 87730, 
Rockford IL, USA). 
Dynamic Light Scattering Measurements 
Hydrodynamic diameters were determined using a Malvern Zetasizer ZS90 particle size 
analyzer, while the scattered light was collected at a fixed angle of 90°. A photomultiplier aperture 
of 400 µm was used with the incident laser power adjusted to obtain a photon counting rate 
between 200 and 300 kcps. Diameter values depended on measurements whereupon the measured 
and calculated baselines of the intensity autocorrelation function had to agree within ±0.1%. All 
determinations were made in multiples of three consecutive measurements of 15 runs each. 
Determination of Electrophoretic Zeta Potential 
Zeta potential (ζ) values for each nanoparticle formulation were determined with a nano 
series Malvern Zetasizer Zeta potential analyzer (Fredrick Seitz Material Research Laboratory, 
University of Illinois at Urbana-Champaign, (MRL facility, UIUC)). Data were acquired in the 
phase analysis light scattering (PALS) mode following solution equilibration at 25 °C when 
calculation of ζ from the measured electrophoretic mobility (μ) employed the Smoluchowski 




Equation 3.1 μ = εζ/η 
where ε and η are the dielectric constant and the absolute viscosity of the medium, respectively.  
Measurements of ζ were reproducible to within ± 2 mV of the mean value given by three 
determinations of 15 data accumulations. 
Transmission Electron Microscopy Imaging 
Two µL of particle suspension was applied to carbon-coated TEM grids. Grids were then 
blotted, air dried, and imaged on a JEOL 2100 Cryo-TEM machine via a Gatan UltraScan 2k × 2k 
CCD camera (MRL facility, UIUC). For bacterial TEM, Bacterial samples were treated at 
concentrations that yielded 50% viability for 3 hours of exposure. Bacteria were then centrifuged 
and washed 3x with dPBS before being flushed with Karnovsky’s Fixative and stored at 4○C until 
imaged.  
Raman and FTIR spectroscopy 
All Raman measurements were taken on a Nanophoton Raman instrument (MRL facility, 
UIUC) with a 532 nm wavelength laser. For each spectrum, a grating (600 l mm-1) scan was taken 
over the range of 120–2700 cm-1. Point scans were performed at 0.2% laser power for one minute 
using a 20x objective. An average of 20 spectra were recorded and averaged per sample.  
For FTIR analysis, aqueous suspensions of particles were drop cast onto MirrIR IR-
reflective glass slides (Kevley Technologies, Chesterland, Ohio, USA) and measured using a 
Nicolet Nexus 670 FTIR (MRL facility, UIUC). For each measurement 100 × 100 μm images were 
collected at 1 cm−1 spectral resolution with 64 scans per pixel and a 25 × 25 μm pixel size and 




Live/Dead Assay with Confocal Microscopy 
After nanoparticle treatments, bacterial cells were washed with 3x with 0.85% NaCl. We 
then used the LIVE/DEAD BacLight Bacterial Viability Kit (Molecular Probes, L7012) to stain 
cells with both SYTO 9 dye (green) and propidum iodide (red). These cells incubated at room 
temperature in the dark for 15 minutes before confocal imaging. Imaging was carried out using a 
Zeiss LSM 710 confocal scanner with a 488 nm laser for both SYTO 9 and Propidium Iodide (all 
lasers were used at 2% laser power). 
Author Contributions 
EAD, SM and DP designed experimental procedures and performed analysis. EAD and 
SM wrote the manuscript. EAD synthesized and characterized particles. GV performed chemical 
synthesis of the prodrug. DS performed NMR measurements. ASD performed electron 






References to Chapter 3 
(1)  Coleman, K. Recent Advances in the Treatment of Gram-Positive Infections. Drug Discov. 
Today Ther. Strateg. 2004, 1 (4), 455–460. 
(2)  Martínez-Martínez, L.; Eliecer Cano, M.; Manuel Rodríguez-Martínez, J.; Calvo, J.; 
Pascual, Á. Plasmid-Mediated Quinolone Resistance. Expert Rev. Anti. Infect. Ther. 2008, 
6 (5), 685–711. 
(3)  Wolfson, J. S.; Hooper, D. C. The Fluoroquinolones: Structures, Mechanisms of Action and 
Resistance, and Spectra of Activity in Vitro. Antimicrob. Agents Chemother. 1985, 28 (4), 
581–586. 
(4)  Hooper, D. C. Mechanisms of Action and Resistance of Older and Newer Fluoroquinolones. 
Clin. Infect. Dis. 2000, 31 Suppl 2 (Supplement 2), S24–S28. 
(5)  Segatore, B.; Setacci, D.; Perilli, M.; Franceschini, N.; Marchetti, F.; Amicosante, G. 
Bactericidal Activity of Levofloxacin and Ciprofloxacin on Clinical Isolates of Different 
Phenotypes of Pseudomonas Aeruginosa. Int. J. Antimicrob. Agents 2000, 13 (3), 223–226. 
(6)  Mohammadhosseini, N.; Alipanahi, Z.; Alipour, E.; Emami, S.; Faramarzi, M.; Samadi, N.; 
Khoshnevis, N.; Shafiee, A.; Foroumadi, A. Synthesis and Antibacterial Activity of Novel 
Levofloxacin Derivatives Containing a Substituted Thienylethyl Moiety. DARU J. Pharm. 
Sci. 2012, 20 (1), 16. 
(7)  Foroumadi, A.; Emami, S.; Mansouri, S.; Javidnia, A.; Saeid-Adeli, N.; Shirazi, F. H.; 
Shafiee, A. Synthesis and Antibacterial Activity of Levofloxacin Derivatives with Certain 




(8)  Zhang, R.; Pan, D.; Cai, X.; Yang, X.; Senpan, A.; Allen, J. S.; Lanza, G. M.; Wang, L. V. 
alphaVbeta3-Targeted Copper Nanoparticles Incorporating an Sn 2 Lipase-Labile 
Fumagillin Prodrug for Photoacoustic Neovascular Imaging and Treatment. Theranostics 
2015, 5 (2), 124–133. 
(9)  Zhou, H.; Yan, H.; Hu, Y.; Springer, L. E.; Yang, X.; Wickline, S. A.; Pan, D.; Lanza, G. 
M.; Pham, C. T. N. Fumagillin Prodrug Nanotherapy Suppresses Macrophage Inflammatory 
Response via Endothelial Nitric Oxide. ACS Nano 2014, 8 (7), 7305–7317. 
(10)  Tomii, Y.; Ozaki, M.; Matsuda, M.; Honmura, T.; Nishimura, I.; Yamaguchi, R.; Adachi, 
T.; Okawa, Y.; Nishino, T. Therapeutic Effect of the Quinolone Prodrug Prulifloxacin 
against Experimental Urinary Tract Infections in Mice. Arzneimittelforschung. 1996, 46 
(12), 1169–1173. 
(11)  Panáček, A.; Kvítek, L.; Prucek, R.; Milan Kolář; Renata Večeřová, ‡; Naděžda Pizúrová, 
§; Virender K. Sharma, *; Tat‘jana Nevěčná, † and; Zbořil†, R. Silver Colloid 
Nanoparticles: Synthesis, Characterization, and Their Antibacterial Activity. 2006. 
(12)  Jung, W. K.; Koo, H. C.; Kim, K. W.; Shin, S.; Kim, S. H.; Park, Y. H. Antibacterial 
Activity and Mechanism of Action of the Silver Ion in Staphylococcus Aureus and 
Escherichia Coli. Appl. Environ. Microbiol. 2008, 74 (7), 2171–2178. 
(13)  Bragg, P. D.; Rainnie, D. J. The Effect of Silver Ions on the Respiratory Chain of 
Escherichia Coli. Can. J. Microbiol. 1974, 20 (6), 883–889. 
(14)  Stein, T. Bacillus Subtilis Antibiotics: Structures, Syntheses and Specific Functions. Mol. 




(15)  Kim, D.; Yu, B. J.; Kim, J. A.; Lee, Y.-J.; Choi, S.-G.; Kang, S.; Pan, J.-G. The 
Acetylproteome of Gram-Positive Model Bacterium Bacillus Subtilis. Proteomics 2013, 13 
(10–11), 1726–1736. 
(16)  Kunst, F.; Ogasawara, N.; Moszer, I.; Albertini, A. M.; Alloni, G.; Azevedo, V.; Bertero, 
M. G.; Bessières, P.; Bolotin, A.; Borchert, S.; et al. The Complete Genome Sequence of 





 CHAPTER 4: NANOCAPSULATION FOR IMPROVED INTRACELLULAR 





Nanoparticles designed as theranostic delivery vehicles have the potential to revolutionize 
personalized medicine. However, the use of theranostic agents in clinical practice is considerably 
hindered by their complex chemistries and synthesis procedures, which create difficulties for their 
encapsulation and delivery efficacy in systemic applications. Although a common solution for 
nano-delivery is the use of liposomes, they tend to release water-soluble payloads accidentally 
during their systemic circulation. The liposome leakage reduces the overall potency of water-
soluble drugs or agents. 
Here we introduce a unique chemical combinatorial solution for enhancing the 
encapsulation and nano-delivery efficiency of water-soluble theranostic agents. Our encapsulation 
procedure is a simple 2-step nanoparticle synthesis method that uses inverted micelle self-
assembly as the agent encapsulation mechanism followed by wrapping in an amphiphilic and 
biocompatible lipid shell, termed the NanoCapsule (NCAP). This method greatly enhances 
hydrophilic encapsulation without sacrificing structural integrity or biocompatibility. A thorough 
nanoparticle characterization revealed that the NCAPs’ architecture maintained long-term stability 
and integrity across different environmental media. Additionally, we showed that the NCAP could 
be adapted to encapsulate a variety of imaging and therapeutic agents by tweaking the chemistries 
of the inverted micelle capsules. Finally, we employed fluorescent methods to measure the 
encapsulation and delivery efficiency of the NCAPs as compared to conventional liposomes on a 
breast cancer cell line. Flow cytometry results showed the NCAPs had a 69.93% greater efficiency 
in cellular labeling over liposomes, whereas live confocal videos confirmed the NCAPs’ ability of 
intracellular delivery as opposed to interacting with the cell membrane alone. Our data supports 




combinatorial theranostics requiring labeled lipids and agent delivery and presents an ideal 
platform for clinical translation. 






Because of their high adaptability, nanoparticles are an ideal platform for delivering 
personalized theranostics to patients and for performing comprehensive preclinical studies of these 
agents.1 Nanoparticles are capable of delivering a range of therapeutic agents to specific locations 
in the body, while they simultaneously facilitate imaging and tracking of the affected tissues. This 
capability has been welcomed by the scientific community, while spurring considerable research 
and advancement. Unfortunately, complex chemistry and synthesis procedures hinder the ability 
of nanoparticles to encapsulate certain agents necessary for specific clinical applications. This 
significant barrier to nanoparticle adoption highlights the lack of a broad and effective platform 
for the encapsulation and delivery of theranostic agents. 
The current solution for packaging and delivering theranostic agents is to trap them within 
the lumen bilayer of liposomes, which enhances biocompatibility and targets tumors via the 
enhanced permeability and retention effect.2 In fact, the first nanomedicine, liposomal doxorubicin 
(Doxil), was approved by the FDA in 1995 and has been used since in a clinical setting for the 
treatment of cancer for the last 20 years.3  
However, liposomes have several limitations that restrict their effectiveness for theranostic 
applications. First, liposomes tend to be “leaky,” which is defined as the passive and unintentional 
release of the contents. This “leakiness” depends on several variables such as water solubility of 
the agent, drug-to-lipid ratio, vesicle diameter, and cholesterol content.4,5 Therefore, the 
“leakiness” reduces the efficiency and potency of water-soluble drugs or agents for reaching their 
desired targets, decreases their overall therapeutic effectiveness, and potentially contributes to 




clearance from the blood by the reticuloendothelial system (RES) and renal clearance, 
respectively.6,7 Coating the liposomes with polyethylene glycol (PEG) can mitigate RES clearance, 
but PEG can also hinder the particles’ controlled release ability at the intended tissue.8,9  
This investigation outlines an innovative solution for packaging water-soluble agents, 
which offers numerous advantages over liposomes and other encapsulation modalities currently in 
use. This encapsulation method employs a simple 2-step phase-transfer chemistry for enveloping 
agents within an inverted micelle capsule and repackaging them with a lipid-based shell to 
maintain biocompatibility for systemic use. These inverted micelles are composed of 12-carbon 
fatty acids where the head groups electrostatically interact with the intended encapsulated agent. 
These inverted micelles are then resuspended within a lipid coating to produce the structure termed 
the NanoCapsule (NCAP).  
Throughout our investigation, we tested the NCAPs’ encapsulation efficiency, stability, 
longevity, biocompatibility, and treatment efficacy. Since most drug varieties come in small 
molecule form, we chose various dyes and the popular chemotherapeutic agent Doxorubicin as our 
agent of encapsulation. We found that the electrostatic interactions between the inverted micelle 
material and the agent of interest (dye or drug) is a significant determinant of the types of molecular 
structures that can be encapsulated. Additionally, the NCAPs’ architecture showed to maintain 
long-term stability and integrity across different environmental mediums. Furthermore, we 
established a biological profile of the NCAP and proved its superior ability as a nanodelivery 
vehicle against liposomes with fluorescent techniques. Specifically, in a flow cytometry 




Based on our findings, we believe our strategy can become a widely-used methodology for 
encapsulating and delivering water-soluble theranostic agents in systemic applications, replacing 
the commonly used liposome variant.  
Results and Discussion 
Our initial experiments began with the aqueous-to-organic transfer of the commonly used 
dye Rhodamine B to test the inverted micelle capabilities for encapsulating and retaining a simple 
molecular structure. A solution of 0.1 mg/ml Rhodamine B was vigorously shaken in equal parts 
volume with 50 mM dodecanoic acid (C12H24O2) solubilized in anhydrous chloroform. The two 
layers are allowed to settle for a prolonged period until the phase transfer was visibly complete 
(Figure 4.1) and is followed by the extraction of the aqueous layer. Dodecanoic acid was chosen 
as the optimal reverse micelle constituent, which resulted in a high amount of Rhodamine B 
transfer. The concentration of Rhodamine B was optimized to ensure that the dodecanoic acid 
inverted micelles were at full payload capacity while ensuring that the presence of residual dye in 
the aqueous layer was less than 1%. The mol/mol optimization ratio between dodecanoic acid and 
Rhodamine B helped control the concentration of dye within the organic layer. 
Once the Rhodamine B molecules have been encapsulated by the inverted micelles within 
the organic chloroform layer, the sample was measured by dynamic light scattering (DLS) to 
compare the diameters of the inverted micelles to their theoretical values. The dodecanoic acid 
inverted micelles had a measured diameter of 3 ± 1 nm with a polydispersity index (PDI) of 0.1 ± 
0.1 (Figure 4.2), whereas the theoretical diameter of the inverted micelle is 3.6 nm (the length of 





Figure 4.1: Schematic representation of rhodamine B transferring from aqueous to organic layers 





Figure 4.2: Histogram representing the number averaged (%) of dodecanoic acid inverted micelles 





To evaluate the selectivity of the dodecanoic acid inverted micelle capsulation, we tested 
two separate solutions of Methylene Blue and fluorescein isothiocyanate (FITC) for their transfer 
capabilities, both at the same concentration of 0.1 mg/mL. Surprisingly, while Methylene Blue did 
transfer from the aqeuous layer to the organic layer (Figure 4.3), FITC did not (Figure 4.4). It can 
be seen from the chemical structure of each dye that the negatively charged dodecanoic acid head 
favors the positively charged amine groups of both Rhodamine B and Methylene Blue. To test this 
observation with FITC, we kept all parameters of the dye transfer process the same, except that 
dodecanoic acid was replaced with dodecylamine (C12H27N); the latter contains a primary amine 
instead of a carboxylic acid on its head group. As expected, FITC did transfer from the aqueous 
layer to the organic chloroform layer only in the presence of dodecylamine, since dodecylamine 
favors the electrostatic interactions with FITC’s negatively charged carboxylic acid group (Figure 
4.4). 
To demonstrate the NCAPs’ applicability in the field of nanomedicine, we chose to test the 
transfer of the popular chemotherapeutic drug Doxorubicin at 0.1 mg/ml using the inverted micelle 
initiating agent dodecanoic acid at 50 mM (Figure 4.5). Our UV-VIS results demonstrate that 
dodecanoic acid facilitated the transfer of 242% more doxorubicin than the control sample 
(control: 34.5 µg; with dodecanoic acid: 83.5 µg) (Figure 4.6). Concentrations of doxorubicin in 




Figure 4.3: Sample image of aqueous Methylene Blue suspension and transfer into dodecanoic 





Figure 4.4: Sample image of aqueous FITC suspension and transfer attempts into dodecanoic acid 











Figure 4.6: Absorbance levels and quantification of dye transferred into dodecanoic acid inverted 





Figure 4.7: a) Doxorubicin concentration-absorbance calibration curve, accompanied by b) the 





After the doxorubicin has been encapsulated into dodecanoic acid inverted micelles, 60 µL 
of the organic chloroform phase was added to a glass bulb along with phosphatidylcholine, 1,2-
dioleoyl-sn-glycero-3-phosphatidylethanolamine, and cholesterol at an optimized w/w ratio of 
10:9:1:0.5 of dodecanoic acid:PC:PE:cholesterol. The organic layer was evaporated to form a thin 
film. This film was flushed with nanopure water (18 MΩ, pH 7.4) and then subjected to probe 
sonication to produce nanoparticles with a final mass concentration of 0.6 mg/mL (Figure 4.8). 
Fresh samples were incubated for 1 h at 4 °C, then filtered (0.22 μm, PTFE) and dialyzed (10,000 
MW) for a prolonged period. 
After the synthesis, the samples were analyzed by DLS to compare their colloidal 
hydrodynamic size changes from the inverted micelle capsules. The NCAPs’ hydrodynamic 
diameter was measured to be 29 ± 10 nm with a PDI of 0.5 ± 0.1 (Figure 4.9). This was followed 
by cryogenic transmission electron microscopy (cryo-TEM) to visualize nanoparticle formation 




Figure 4.8: Schematic representation of the NCAP synthesis process from the inverted micelle 





Figure 4.9: Histogram representing the number averaged (%) of NCAPs with an overlaid image of 





Since we hypothesized that these nanoparticles were robust for systemic use and would 
enhance intracellular delivery, we analyzed their surface charge and stability profile. Since 
nanoparticle surface charge is a well-known determinant of cellular internalization efficiency and 
systemic stability,10,11 we investigated the NCAPs’ Zeta potential. Zeta readings showed the 
NCAPs registered at -25 ± 5 mV, which falls in the ideal range between −20 mV and −40 mV and 
is suitable for cellular internalization and multi-environment stability. To measure their stability 
profile, we placed the NCAP in the following aqueous solutions at 37 ○C and monitored its 
hydrodynamic diameter by DLS over the course of 1 week: nanopure H2O, dPBS (pH 7.4), pH 
4.5, pH 7.4, pH 12 (pH was controlled with HCl and NaOH). The NCAPs were found to be 
significantly stable over time in each environmental formulation except for the pH 4.5 solution 
(Figure 4.10). This sudden change in stability is indicative that severely acidic conditions, such as 
the localized environment of a tumor,12–14 is ideal for NCAPs’ disassociation and payload release. 
To test the NCAPs’ release profile, we measured Doxorubicin-loaded NCAPs, 
Doxorubicin-loaded liposomes (prepared according to literature standards; Lee et al.15), and free 
Doxorubicin for Doxorubicin content by UV-VIS over one day while dialyzed in a 10,000 MW 
cassette against nanopure water (18 MΩ). As expected, free Doxorubicin dissipated from the 
dialysis cassette within minutes, while the liposome variation took 1.5 hours to release 69.6% of 
its payload. Contrarily, the Doxorubicin-loaded NCAPs released 63.2% of its payload after 3.5 




Figure 4.10: One week assessment of the NCAP’s Hydrodynamic diameter stability in various 
environments. 
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Figure 4.11: Dialysis release profile of doxorubicin from liposome and NCAP samples over 7 
hours, compared to free doxorubicin. 
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Cellular Delivery and Uptake Profile 
To create a biological characterization profile of the NCAPs, we performed an initial 
toxicity test with Doxorubicin exposure to the triple-positive breast cancer cell line MCF-7. The 
samples chosen for treatment included a control sample of the NCAP alone, NCAP loaded with 
Doxorubicin, and a sample of Doxorubicin alone at the equivalent concentration of the NCAP 
loaded version. Using the standard MTT assay, we found that the NCAP performed better at 
delivering the payload contents intracellularly and thus proved to be more toxic than the free 
Doxorubicin treatment. The control NCAP sample did not show signs of toxicity because of it’s 
makeup of biocompatible materials (Figure 4.12). 
For a more thorough quantification of the NCAPs’ nano-delivery efficiency as compared 
to liposomal delivery, we labeled both nanoparticle types with the fluorescent lipid 1,2-Dioleoyl-
sn-Glycero-3-Phosphoethanolamine-N-(Carboxyfluorescein) (F-PE) and measured their treatment 
efficiencies on MCF-7 cells by flow cytometry. The fluorescence data showed two separate and 
unique histograms of each particle variant where the NCAP sample clearly exceeds the liposomal 
sample in arbitrary intensity units (Figure 4.13). To quantify this difference, we subtracted the 
histograms according to the Cumulative-Overton method; the results then indicated that 69.93% 
of NCAP-treated cells were deemed positive (had significantly higher F-PE expression) over 




Figure 4.12: Percent change in MCF-7 cell viability at different treatment concentrations. 
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Figure 4.13: Flow cytometry histogram analysis of cells treated with an F-PE labeled Liposome, 
and an F-PE labeled NCAP. The liposome histogram was subtracted from the NCAP histogram 
by Cumulative Overton method, and NCAP-Treated cells which were identified to have more 
fluorescence expression than liposome-treated cells are labeled in dark red. A histogram of control 
cells is shown for reference. 
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To visualize this interaction at the cellular level, we employed confocal microscopy on 
MCF-7 cells treated with both the liposome and NCAP variants; both samples were loaded with 
Rhodamine B and labeled with F-PE. Our confocal micrographs demonstrate that both 
nanoparticle variants delivered their Rhodamine B payload within the cells; however, the entire 
NCAP structure was were delivered intracellularly along with its payload, whereas the liposomes 
only bonded with the lipid-rich cell membrane (Figure 4.14a, b). Furthermore, liposome-treated 
cells showed a high frequency of localized nanoparticle clusters at the perimeter of the cell, 
whereas NCAPs were localized within the cell lumen (white arrows in Figure 4.14a, b). The 
difference in localization indicates that the NCAPs’ delivery system is more efficient in cellular 
internalization than liposomal particles; this is an important consideration for theranostic 
applications involving prodrugs or lipid-labeled imaging agents that require the whole particle to 
be internalized to be effective. A final observation to consider is the presence of large numbers of 
fluorescent nanoparticles within the nucleus of the NCAP-treated cells, which suggests that the 
NCAP is either able to penetrate the nucleus, or that the nanoparticle breaks down within the cell, 
and its material compositions then disperses into the nucleus. Nonetheless, this NCAPs’ 





Figure 4.14: Confocal images of MCF-7 cells treated with an F-PE labeled a) liposome or b) 




The distinct phenomenon of NCAPs’ protrusion into cellular nuclei prompted us to 
undertake an in-depth examination of the NCAPs’ interactions with cells. Thus, we employed live 
confocal imaging to visualize this interaction in vitro. Live cells were stained with DAPI 30 
minutes prior to treatment with F-PE labeled liposome or NCAP samples. Cells were then treated 
and imaged every 5 seconds to monitor their interactions with the fluorescent liposomes. We found 
that cells treated with fluorescent liposomes began to show stained cell membranes within 1 
minute, similarly to what was viewed in static confocal microscopy (Figure 4.15, Video 1: F-PE 
Labeled Liposome2). Conversely, the fluorescently-labeled NCAPs were found inside of the cells 
as fluorescent artifacts after only 5 minutes of imaging (Figure 4.16, Video 2: F-PE labeled 
NCAP3). This behavior supports our predictions that liposome-based delivery is efficient at 
reaching the cell, yet the unique nanoarchitecture of the NCAP allows for higher-throughput 
cellular internalization and agent retention. 
                                                 
 
2 Live confocal Images of MCF-7 cells being treated with F-PE labeled liposomes. White arrows point to 
areas of cells where the liposomes collected at the cell membranes. Images were taken once every 5 seconds. (40X 
Objective) 
3 Live confocal Images of MCF-7 cells being treated with F-PE labeled NCAPs. White arrows point to areas 





Figure 4.15: Still confocal images of MCF-7 cells while treated with an F-PE labeled liposome. 
Stills were taken from live recording at 0, 5, and 300 Seconds. White arrows point to collection of 
F-PE liposomes which were collected on cell surfaces. Arrows are maintained through the time 
series for consistency (40x objective). 
Figure 4.16: Still confocal images of MCF-7 cells while treated with an F-PE labeled NCAP. Stills 
were taken from live recording at 0, 5, and 300 Seconds. White arrows point to fluorescent NCAP 







Here we have investigated the next generation of nanoparticle delivery by designing a 
nano-architecture, termed NCAP, for high-throughput internalization into cells. This type of nano-
delivery vehicle is adaptable for a multitude of theranostic uses and has the potential to improve 
the efficacy of theranostic agents for inhibiting or detecting intracellular activity. Furthermore, the 
NCAPs’ lipid-based shells make them ideal nano-delivery vehicles for combinatorial therapy that 
combines lipid-based molecules (such as imaging labels, targeting moieties, or prodrugs), and a 
hydrophilic agent entrapped within the NCAPs’ inverted micelle capsules.  
Within this detailed investigation into the possible functions of such a versatile capsule, we 
considered pushing its chemical boundaries by propagating the encapsulation of multiple dyes with 
differing molecular structures. We then transferred these capsules into aqueous and biocompatible 
nanoparticles facilitated by a simple lipid wrapping technique and tested their intracellular delivery 
capabilities on the metastatic breast cancer cell line, MCF-7. 
We then compared the NCAPs’ cellular interactions with the commonly used liposome 
nanoparticles through quantitative and visual data. Flow cytometry experiments indicated that the 
NCAPs were 69.93% more effective at labeling MCF-7 cells over liposomes, while confocal-based 
imaging and live video recordings detailed the NCAPs interactions at the cellular level. These 
fluorescent techniques demonstrated the NCAPs’ ability to surpass cell membrane interactions 
and, in fact, deliver their contents into the cell’s lumen, while liposome treatments were confined 
to membrane interactions alone.  
Additional investigations are warranted in the future for the capability of the NCAPs to 




Additionally, the NCAPs’ in vivo adaptability and systemic clearance must be established to 
translate this novel delivery platform into clinical use. 
Methods 
Unless stated otherwise, all material and reagents were purchased from Sigma–Aldrich, St. 
Louis, MO, and were used without further purification. Solvents were used as received and without 
further purification. 
Inverted Micelle Transfer 
An equal volume ratio of 50 mM of dodecanoic acid dissolved in chloroform and an 
aqueous suspension of either Rhodamine B (100 µg/ml) or Doxorubicin (100 µg/ml) was added 
into a 1-dram (3.7 ml) vial and vigorously shaken for several seconds to homogenously mix the 
layers. The vials were then allowed to separate and settle for a prolonged period of time. At this 
point, the small molecule variation of choice had clearly transferred into the chloroform layer. 
Nanocapsule Formation 
The inverted micelle-dye/drug composite, while suspended in chloroform, was added to a 
glass bulb along with phosphatidylcholine (PC, Coatsome, NOF Corporation, Tokyo, Japan), 1,2-
Dioleoyl-sn-glycero-3-phosphatidylethanolamine (PE, Cayman Chemical Company, MI, USA), 
and cholesterol at an optimized w/w ratio of 10:9:1:0.5 of dodecanoic acid:PC:PE:cholesterol. The 
chloroform in the glass bulb was evaporated by a rotary evaporator (RE200, Yamato Scientific 
Co., Ltd. Japan) in a 55 °C water bath to produce a thin film layer of the materials. The sample 
was then placed in a desiccator (Labconco, Kansas City, MO, USA) for 30 minutes. Water (pH 




0.8 mg/ml. The sample was subject to probe sonication for 30 seconds (Amp: 1, On: 2 sec, Off: 
2 sec). The samples were then immediately placed in an ice-bath and incubated for one hour at 4 
°C. Following incubation, the samples were filtered through a 0.22 μm PTFE syringe filter and 
dialyzed against a 10,000 molecular weight cut off cassette (Thermo Scientific Product # 87730, 
Rockford IL, USA). 
Dynamic Light Scattering Measurements 
Hydrodynamic diameters were determined using a Malvern Zetasizer ZS90 particle size 
analyzer, while the scattered light was collected at a fixed angle of 90°. A photomultiplier aperture 
of 400 µm was used with the incident laser power adjusted to obtain a photon counting rate 
between 200 and 300 kcps. Diameter values depended on measurements whereupon the measured 
and calculated baselines of the intensity autocorrelation function had to agree within ±0.1%. All 
determinations were made in multiples of three consecutive measurements of 15 runs each. 
Organic samples were measured in a quartz cuvette. 
Determination of Electrophoretic Zeta Potential 
Zeta potential (ζ) values for each nanoparticle formulation were determined with a nano 
series Malvern Zetasizer Zeta potential analyzer (Fredrick Seitz Material Research Laboratory, 
University of Illinois at Urbana-Champaign, (MRL facility, UIUC)). Data were acquired in the 
phase analysis light scattering (PALS) mode following solution equilibration at 25 °C when 
calculation of ζ from the measured electrophoretic mobility (μ) employed the Smoluchowski 
equation, which is expressed as: 
Equation 4.1 μ = εζ/η 




Measurements of ζ were reproducible to within ± 2 mV of the mean value given by three 
determinations of 15 data accumulations. 
Cryo-Transmission Electron Microscopy Imaging 
Two µL of nanoparticle suspension was applied to carbon-coated TEM grids. Grids were 
then rapidly blotted, and immediately plunged into liquid methane kept at -200○C. The samples 
were stored in -200○C liquid methane until imaged on a JEOL 2100 Cryo-TEM machine via a 
Gatan UltraScan 2k × 2k CCD camera (MRL facility, UIUC). 
Cell Viability Assay 
The cytotoxic effect of nanoparticle formulations were investigated with a 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The MCF-7 (human 
estrogen receptor positive breast cancer) cell line was plated on a 96-well plate at a density of 
12,000 cells per well (Greiner CellStar® 96 well plates, Sigma-Aldrich, MO, USA) and exposed 
to nanoparticle formulations after 24 hours at 37 °C. Followed by a 48 h exposure time, 20 μL 
(5 mg/mL) of MTT solution was added to each well and cells were further incubated for another 4 
hours. After exposure, media was aspirated, and 200 μL of dimethyl sulfoxide (DMSO, ≥99%, MP 
Biomedicals, USA) was added to dissolve formazan crystals. The optical density of samples was 
determined by Synergy HT (BioTek, USA) with a reference wavelength of 570 nm. The following 
equation determined percentage cell viability: 










Flow Cytometry samples were performed on cells (cell density: 500 cells/µL) treated with 
10% v/v of each sample and measured on a Guava® EasyCyte Plus Flow Cytometer. For each 
sample data from 3000 single cell events were collected within 3 minutes at an excitation of 488 
nm. Measurements were run in triplicates. 
Confocal Microscopy 
For static confocal microscopy, the MCF-7 cell line was plated on poly-L-lysine coated 
circular coverslips at a cell density of 400,000 cells per 25 mm coverslip. After 24 hours, cells 
were treated with respective components (Nanoparticles, F-PE, and/or Rhodamine) and then fixed 
using 8% paraformaldehyde. Cells were then stained with DAPI containing Vectashield mounting 
medium prior to imaging. Imaging was carried out using a Zeiss LSM 710 confocal scanner with 
the following lasers: 405 nm for DAPI, 488 for F-PE, and 561 nm for Rhodamine (all lasers were 
used at 2% laser power). 
For live confocal, samples the MCF-7 cell line was plated on poly-L-lysine coated Ibidi µ-
Slide 8 well plates  at a cell density of 30,000 cells per well. After 24 hours, cells were placed in a 
Zeiss LSM 880 Airyscan confocal scanner with an attached incubation chamber. Cells were kept 
in the chamber at 37.1○C with a constant flow of CO2 at 5.3% and humidity levels at 87%. Cells 
were replenished with fresh media as needed prior to imaging. Cells were pre-stained with DAPI 
(AAT Bioquest) 30 minutes prior to imaging, at a concentration of 5 µM. Cells were imaged at 1 
frame per 5 seconds with a 405 nm laser at 4% laser power for DAPI and a 488 nm laser at 4% 
laser power for F-PE. Once imaging commenced, cells were treated with respective components 
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 CHAPTER 5: A FACILE CHEMICAL STRATEGY TO HYDROPHOBICALLY 
MODIFY SOLID NANOPARTICLES USING INVERTED MICELLES FOR 








Theranostic nanoparticles have incredible potential for biomedical applications by 
enabling visual confirmation of therapeutic efficacy. Numerous issues challenge their clinical 
translation and are primarily related to the complex chemistry and scalability of synthesizing 
Nanoparticles. We report a 2-step chemical strategy for high-throughput intracellular delivery of 
organic and inorganic solid nanoparticles. This process takes an additional step beyond 
hydrophobic surface modification, towards the packing of multiple solid nanoparticles into a soft-
shelled lipid capsule, termed the Nano-MultiCapsule (NMC). This technique is high yielding and 
does not require the complex purification steps in anaerobic/hydrophobic reactions for 
hydrophobic modification. To demonstrate the efficacy across different material compositions, we 
separately entrapped ~10 nm gold and carbon nanoparticles (AuNP and CNP) within NMCs, then 
quantified their internalization in a human breast cancer cell line. For encapsulated AuNPs (NMC-
AuNP), we confirmed greater cellular internalization of gold through ICP-OES and TEM analyses. 
Raman spectroscopic analysis of cells treated with encapsulated CNPs (NMC-CNP) also exhibited 
high degrees of uptake with apparent intracellular localization as opposed to free CNP treatment. 





Nanoparticles have shown significant potential to redefine conventional medicine. 
Biomedical applications of nanoparticles are mainly centered around early detection and treatment 
of a disease. Some cases demonstrate that ‘theranostic’ nanoparticles allow physicians to track the 
effectiveness of their treatment in patients.1,2 Although there have been comprehensive preclinical 
studies of these agents, the eventual success of clinical translation has not been fully realized. 
Numerous issues related to their development, such as scale-up feasibilities, regulatory aspects, 
and commercialization challenges their clinical translation. The chemistries involved in theranostic 
nanoparticle engineering allow for precise tuning of shape, size, and surface chemistry to better 
enable circumstantial requirements to serve a specific, or a multitude, of purposes.3–6 Although the 
size of nanoparticles is directly correlated to retention time,7,8 particles for systemic use have an 
ideal nanoparticle diameter of 10 nm or less because the glomular filtration apparatus in the kidney 
possesses an effective size cut-off at 10 nm.9 As a result of this cut off size, nanoparticles with 
sizes under this threshold tend to rapidly clear the body’s blood stream, thus decreasing chances 
of accidental particle accumulation, and nanoparticle exposure to vital organs.10–15 From these 
physiological paradigms, which pose issues for both small (<10 nm) and large (10-300 nm) 
particles, there has been only marginal success in solid nanoparticle applications. There is great 
value for synthetic methodologies which may alleviate certain constraints in attaining FDA 
approval for nanoparticle based treatments. Towards this aim, we disclose a simple chemical 
strategy for high throughput intracellular delivery of <10 nm solid nanoparticles. This unique 
process involves a simple hydrocarbon ‘wrapping’ technique driven by inverted micelle formation 
to encapsulate <10 nm solid nanoparticles. The technique is high yielding and does not require an 
anaerobic hydrophobic reaction that normally involves complex purification steps. Parallel to 
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improving the in vitro delivery of 10 nm nanoparticles, this methodology is unrestricted to 
inorganic or organic material varieties, thus making it a versatile method for high throughput 
nanoparticle delivery. 
One challenging aspect of rendering nanoparticles has been the requirement to stabilize its 
surface with biocompatible and nonreactive coating agents. The nanoparticle encapsulation vehicle 
should allow the colloidal system to stay suspended in aqueous media for a desired period and 
avoid unfavorable interactions with hydrophilic counterparts in systemic circulation. Furthermore, 
and equally as important, the nanoparticle capsule should facilitate any type of surface 
functionalization intended to diagnose or treat the intended delivery target. Without such a robust 
and multifunctional coating, proteins may absorb non-specifically to the surface leading to poor 
efficacy in nano-delivery. Currently, phospholipids and polymers are used to coat hydrophobically 
modified inorganic oxides or metal nanoparticles. Unfortunately, hydrophobic surface 
modifications can be particularly challenging for solid nanoparticles since some synthesis methods 
may require the use of organic media in an anaerobic environment. A simple yet universal coating 
strategy for nanoparticles is thus desirable to convert pristine cores without requiring complex 
chemistries. An avenue to address these issues consists of a ‘particle-in-particle’ approach by 
encapsulating nanoparticles within inverted micelles independent of their material composition. 
Based on these factors, we chose to investigate two commonly used solid nanoparticle 
compositions, i.e. gold and carbon for this study. Gold nanoparticles (AuNP) have been 
extensively characterized for theranostic approaches because of their attractive bio-compatibility 
and facile modification of surface functionalities.16–18 Application’s for AuNPs range from nucleic 
acid functionalization,19,20 drug delivery,21 contrast agents across an array of modalities,22–24 and 
even photothermal therapy.25,26 Carbon nanoparticles (CNP) are rising for their incredible 
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properties with fluorescent,27–30 infrared,27 and Raman imaging.27–30 CNPs have been tuned with 
various passivations to control size, surface chemistry, and biocompatibility.27 Concurrently, 
CNPs have been used for delivery of various small molecules,31,32 nucleic acids,33 and enzymes.34 
Our strategy utilizes inverted micelles composed of fatty amines as a container to 
hydrophobically and non-covalently modify/encapsulate solid nanoparticles as a prerequisite to 
induce hydrophobic-amphiphilic self-assembly within lipid capsules, termed the Nano-
MultiCapsule (NMC). With our research methodologies, we found that in vitro treatments of 
AuNP encapsulated by NMCs were quantifiably superior at cellular uptake compared to AuNP 
interactions alone. Furthermore, the NMC delivery vehicle showed similarly high-efficacy for 
intracellular CNP delivery, as measured by in vitro spectroscopic Raman analysis. Both cases show 
that the NMC nano-architecture proved to surpass the passively treated intracellular delivery of 
~10 nm particle. 
Results and Discussion 
Nanoparticle characterization and inverted micelle induced passivation 
AuNPs were synthesized via sodium borohydride reduction and capped with trisodium 
citrate. Ratios of gold chloride (HauCl4), trisodium citrate (Na3C6H5O7), and sodium borohydride 
(NaBH4) were optimized to ensure ~10 nm nanoparticle formation and consistency per batch while 
maintaining strong surface plasmon characteristics. To determine the AuNP size distribution and 
to confirm that particles meet limitations for renal clearance, we measured the hydrodynamic 
diameter of the AuNP suspension by dynamic light scattering (DLS). The optimized AuNPs had a 
measured hydrodynamic diameter of 8 ± 2 nm with a polydispersity index (PDI) of 0.5 ± 0.1 when 
measured for ‘Population-by-Number’ (Figure 5.1). A ‘Population-by-Intensity’ DLS 
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measurement revealed a sub-population of particles with a hydrodynamic diameter of 214 ± 56 
nm and a PDI of 0.2 ± 0.1 prior to filtration (Figure 5.2). Transmission electron micrographs 
(TEM) of AuNP samples supported our assumption that the smaller sized AuNP population was 
the most abundant in the suspension (Figure 5.1 inset). Additionally, anhydrous diameters were 
measured by ImageJ to be 5 ± 0 nm (n = 264), due to dehydration and loss of ionic corona. 
Nonetheless, large particles were allowed to settle and were filtered out (0.22 µm) before in vitro 
treatments. UV-Vis analysis resulted in a characteristic plasmonic absorbance peak at 528 nm (red 
in color) (Figure 5.3, Figure 5.4). The addition and agitation of the AuNP aqueous suspension with 
a 16.2 mM solution of dodecylamine in chloroform resulted in the spontaneous transfer of the 
water-soluble AuNPs into the organically soluble inverted micelles. The sample was labeled as 
‘IM-AuNP’ for inverted micelle encapsulated gold nanoparticles. This spontaneous phase transfer 
did not occur in a control sample where the organic solution lacked the fatty amine (Figure 5.4). 
The favorable electrostatic interactions between the carboxylate groups on the surface of the 
citrate-capped AuNPs and the amine group of dodecylamine provides a plausible mechanism for 
this spontaneous phase transfer; thus, resulting in a non-covalent hydrophobic hydrocarbon coating 
on the gold nanoparticle’s surface (Figure 5.4). To confirm these surface interactions, the 
vibrational energies of the surface chemistry were analyzed by fourier transform infrared (FTIR) 
analysis. The IM-AuNP organic suspension revealed peak shifts of the Amide I (1648  1671 cm-
1) and Amide II (1556  1565 cm-1) peaks (Figure 5.5), confirming that the amine-carboxylate 
interaction is the primary driving mechanism for inverted micelle encapsulation. A DLS analysis 
of the remaining aqueous supernatant (after transferring AuNP’s into the inverted micelle) 
revealed that the larger AuNPs were still present and the small AuNP population had disappeared 
(Figure 5.2). This result implies that the inverted micelle encapsulation process acts as a size 
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selective barrier to ~10 nm particles. Additionally, we observed that the AuNP’s color and plasmon 
characteristic remained after transferring into the organic layer (Figure 5.4), indicating that the 
dodecylamine shell protects AuNP from the harsh organic environment. A follow-up UV-Vis 
spectral measurement of the IM-AuNP in chloroform solution revealed the surface plasmon peak 
shifted from 528 nm to 518 nm, supporting our conclusion that the larger AuNP population is not 
present in the organic solution (Figure 5.3).35  
To synthesize CNP, we modified a method based on Misra et al. and Daza et al. which uses 
agave nectar as the primary carbon source and polyethylene glycol (PEG) as the capping agent.36,37 
We chose the optimized mass ratio of 1:10 (agave: PEG) to form small biocompatible and highly 
spectroscopic CNPs. The CNPs were then characterized by DLS (hydrodynamic diameter: 9 ± 2 
nm, with PDI of 0.3 ± 0.0) and TEM (Figure 5.6) (anhydrous diameter: 7 ± 1, n = 145) to ensure 
they met our <10 nm particle diameter qualifications. 
While the AuNP’s SPR characteristics work well for IR imaging based applications,16,38 
CNPs have a spread of unique optical and fluorescence based properties.36 We characterized the 
spectroscopically active CNPs by their fluorescence profile which revealed two separate excitation 
wavelengths at 210 nm and 350 nm, while maintaining a common emission wavelength at 450 nm 
(Figure 5.7). The robustness of CNP’s fluorescent property can be analyzed by assessing the 
carbon-carbon bond arrangement through Raman spectroscopy since it is well known that adequate 
graphene stacking can promote spectroscopic activity from π -π interactions due to resonant 
electron relaxation.39 A Raman spectral analysis revealed that CNPs are dominantly graphitic due 
to the graphitic and diamond band intensity ratio (IG/ID ratio) of 1.13 (Figure 5.8), indicating that 
sp2 bond hybridization is more prevalent within the system. Therefore, CNPs can be considered 
spectroscopically robust, and thus, qualify for further probing into theranostic applications. 
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Figure 5.1: Histogram representing the number averaged (%) of AuNPs with an inset of a TEM 





Figure 5.2: An overlaid histogram comparing the intensity averaged (%) of the AuNP stock 





Figure 5.3: UV-Vis absorbance measurements of the AuNP stock suspension (magenta) and post 
transfer organic layer (dark purple). 
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Figure 5.4: Schematic representation of solid nanoparticles transferring from aqueous to organic 





Figure 5.5: FTIR Spectral analysis of AuNP, dodecylamine (C12H25NH2), and IM-AuNP with 
respective peak wavenumbers. 
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Figure 5.6: Histogram representing the number averaged (%) of CNPs with an overlaid image of 










Figure 5.8: Raman spectral analysis of the CNP’s graphitic and diamond-like characteristics with 



























To ensure nanoparticle compatibility with fatty amine driven encapsulation, we measured 
the chemical composition of the CNP’s surface by FTIR spectral analysis. CNP spectrographs 
show reoccurring hydroxyl peaks and significant artifacts indicating C-OH stretching at 3350 cm−1 
which is indicative of H-bonding occurring within the system (Figure 5.9). This h-bonding activity 
is imperative to initiate inverted micelle transfer between the carboxylic acid groups on the CNP’s 
surface and the amine groups on dodecyl amine. Similar to the AuNPs, the CNP suspension 
successfully transferred to the 16.2 mM dodecylamine-chloroform solution as expected (Figure 
5.10), while the control sample (lacking dodecylamine) did not initiate a CNP transfer to the 
organic layer.  
Design and synthesis of the Nano-MultiCapsule 
The outer shell of the NMC system is strategically composed of soybean-derived lecithin 
because of its history of physiological biocompatibility and FDA approval. To produce each NMC 
variation, soybean lecithin was added to the organic suspension of inverted micelle encapsulated 
nanoparticles (IM-AuNP or IM-CNP) then processed through a rotary evaporator to remove the 
organic solvent. The exact proportion and composition of materials in the organic suspension was 
optimized to generate NMCs in the 10-100 nm range to undergo the enhanced permeability and 
retention effect.40 The thin film was subsequently resuspended in pH 7.4 Dulbecco's phosphate 
buffered saline (dPBS) and probe sonicated to produce colloidal NMCs (Figure 5.11). These 




Figure 5.9: a) FTIR spectral analysis of CNP’s chemical composition and (b) a near infrared 












Figure 5.11: Schematic representation of the NMC synthesis process from the inverted micelle 





For naming convention, a group of AuNPs encapsulated in an NMC is labeled as NMC-
AuNP, and a group of CNPs encapsulated into an NMC is labeled as NMC-CNP. The 
hydrodynamic diameter of NMC-AuNPs was measured to be 31 ± 10 nm with a PDI of 0.5 ± 0.1, 
while NMC-CNPs was measured to be 40 ± 6 nm with a PDI of 0.4 ± 0.1 (Figure 5.12). If we 
assume that the solid nanoparticles randomly pack within the NMC architecture, we can predict 
that the average particle per NMC-AuNP is 37 and NMC-CNP is 56 based on the Kepler random 
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Nanoparticle surface charge is a well-known determinant of cellular internalization 
efficiency and systemic stability. In fact, receptor mediated endocytosis (RME) is dependent on 
the electrostatic interactions occurring between nanoparticles and cell membrane proteins on the 
molecular level43,44. For this reason, we investigated nanoparticle Zeta measurements on each 
NMC formulation to determine their electrophoretic potential. Zeta potential readings confirmed 
our initial findings that both solid nanoparticle variations had strong negative surface charges due 
to carboxylate-based surface chemistries. The adjacent NMC variations had ‘less negative’ Zeta 
readings which predicts a higher rate of cellular uptake while maintaining a negative charge 
necessary for systemic stability (Figure 5.13).44
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Figure 5.12: An overlaid histogram representing the number averaged (%) of the NMC-AuNP and 
NMC-CNP colloidal hydrodynamic diameters. 
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To understand the dynamic stability of the NMC architecture, the hydrodynamic diameter 
for each NMC variation was monitored for one week at 37 °C in the following environments: Low 
pH H2O (pH 4.5, HCl), dPBS (1x, pH 7.4), high pH H2O (pH 12, NaOH), and fetal bovine serum 
(FBS, 1%). Both NMC-AuNP and NMC-CNP remained consistent with their hydrodynamic 
diameter integrity (Figure 5.14), which was additionally supported by long-term stability studies 
at 4 °C over 1 month of observation (Figure 5.15). TEM micrographs of NMC-AuNP particles 
revealed a large population of AuNP aggregates with anhydrous diameters similar to the reported 
hydrodynamic diameters (Figure 5.16). Furthermore, a UV-Vis absorbance analysis on the NMC-
AuNP suspension revealed a red 20 nm peak shift to 526 nm, commonly seen through aggregation 
(Figure 5.17). To further probe that the NMC-AuNP structure displays shell-like characteristics, 
samples underwent small angle X-Ray scattering (SAXS). The X-Ray patterns revealed a strong 
q band intensity at 0.54 nm-1 indicating the presence of an 11.6 nm artifact (Figure 5.18). Since 
the AuNP’s have diameters of 8 ± 2 nm and the dodecylamine shell adds an additional 3.68 nm to 
the diameter (1 dodecylamine ~ 1.84 nm; 1.84 nm *2 = 3.68 nm) then the 11.6 nm SAXS artifact 
falls within an expected range for the hydrophobically passivated AuNPs. 
TEM micrographs of NMC-CNP particles also showed a commonly sized population 
corresponding to the measured hydrodynamic diameters. A TEM inset at a higher magnification 
reveals the smaller groupings of individual CNPs with the NMC (Figure 5.19). A normalized UV-
Vis absorbance measurement of the NMC-CNP suspension showed a decrease in the typical CNP 
absorbance peak at 282 nm as compared to the stock CNP spectra (Figure 5.20). This decrease is 
a result of the NMC phospholipid outer shell obstructing light interactions with the CNP’s surface 
chemistry that determine the CNP’s inherent optical properties.  
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Figure 5.14: Seven-day assessment of (a) NMC-AuNP and (b) NMC-CNP Hydrodynamic 
diameter stability in various environments. 
 
 
Figure 5.15: A 30-day assessment of the NMC Hydrodynamic diameter shelf life stability at 4 °C. 
 
  


































Figure 5.17: UV-Vis absorbance measurements of the AuNP stock suspension (Magenta) and 





Figure 5.18: a) SAXS intensity versus q (nm-1) with visible feature indicated by black arrow. a) 





Figure 5.19: TEM micrographs of NMC-CNP with an inset at a higher magnification. Arrows 





Figure 5.20: UV-Vis absorbance measurements of the CNP stock suspension (dark) and NMC-





NMC biocompatibility profile and cellular internalization analysis 
Since many studies show that AuNPs and CNPs have minimal to no biological 
interference,36,45 we investigated the biocompatibility of the NMC-AuNP and NMC-CNP to ensure 
biocompatible consistency after nanoparticle encapsulation. To test biocompatibility, a 2-D culture 
of MCF-7 was seeded in triplicate, at a density of 10,000 cells per well, for nanoparticle 
cytotoxicity measurements by an MTT reduction assay. MCF-7 cells were then subject to various 
concentrations of AuNP, CNP, NMC-AuNP, NMC-CNP, and an empty NMC shell. After 48 hours 
of exposure, AuNPs and CNPs showed cell viability trends at or above 100% as expected due to 
their known bio-inert characteristics (Figure 5.21a).  
Agreeably, both the NMC-AuNP and NMC-CNP counterparts supported trends at or above 
100% cell viability for expected treatment concentrations. These results are expected since the 
empty NMC capsules showed no signs of severe toxicity due to its material composition except at 
the highest concentration tested where the cell population dipped to roughly 80% viability (Figure 
5.21b). To be certain that the NMC particles did not physically disrupt cellular morphology, we 
examined bright field images of MCF-7 cells at the highest treatment concentrations (0.1 mg/ml) 
to ensure that cellular structure was not compromised. After 48 hours of exposure, we found that 
both treatment variations did not create noticeable morphological impairments, but instead closely 
resembled the control cells (Figure 5.22a-c). Both MTT and bright field experiments indicate that 
the NMC encapsulation process of hard nanoparticles did not affect the particle’s biocompatibility, 
which is significantly relevant when investigating alternative methods for high-throughput 
delivery of small nanoparticles.
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Figure 5.21: a) Percent change in MCF-7 cell viability of AuNP and CNP. b) Percent change in 





Figure 5.22: a-c) Bright field images of MCF-7 cells treated at 0.1 mg/ml of the labeled samples. 





Enhanced ~10 nm AuNP cellular internalization 
To validate our hypothesis that the NMC architecture improves solid nanoparticle 
internalization into diseased cells, we used inductively coupled plasma – optical emission 
spectrometry (ICP-OES) to quantify the content of gold internalized per cell for AuNP and NMC-
AuNP samples. MCF-7 treatment concentrations of NMC-AuNP were optimized at 0.5 mg/ml to 
deliver minimal but noticeable results, while AuNP treatments were performed at a gold content 
equivalence to the NMC-AuNP. Cells were exposed to these formulations for four hours (2×106 
cells/ dish), washed with dPBS (pH 7.4) three times, trypsinized, and collected for ICP-OES. A 
duplicate treatment underwent 3x heparin-sulfate washes instead of dPBS to remove any AuNP 
that might have remained on the surface of cells to differentiate from endocytosed AuNP.46 In each 
case, ICP-OES results determined that the NMC-AuNP delivered a significantly larger amount of 
elemental gold within the cell than treatments of free AuNPs (Figure 5.23). When each formulation 
was compared to its duplicate heparin sulfate wash, the AuNP sample decreased in gold-per-cell 




Figure 5.23: ICP histogram analysis of elemental gold per cell after treatments with AuNP, NMC-
AuNP, and a duplicate of each variation with an added heparin sulfate wash (indicated by ‘-H’ 
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This difference in elemental gold content within the cell is indicative that the ~10 nm AuNP 
treatment must collect on the surface of the cell membrane and cannot activate sufficient receptors 
for RME as compared to the NMC-AuNP variant which carried a packaged payload of the smaller 
AuNPs. Therefore, we can conclude that the NMC architecture drives high-throughput 
intracellular nanoparticle internalization. To visualize this AuNP uptake phenomenon, we 
considered cellular TEM imaging after a 2-hour treatment of each variation at 5x the normal 
treatment concentrations. MCF-7 cells were treated with concentrations similar to ICP-OES 
measurements and then fixed with glutaraldehyde. TEM micrographs of cells treated with just 
AuNPs showed infrequent and disperse particles (Figure 5.24a). In some cases, intercellular 
vesicles were found to have ~10 nm gold nanoparticles lining the vesicle perimeter suggesting 
RME may have driven cellular uptake (Figure 5.24b), although this was not frequently observed. 
When compared to TEM micrographs of NMC-AuNP treatments, there was an abundant amount 
of internalized AuNP clusters indicating that the NMC architecture facilitated the high-throughput 
cellular internalization of AuNPs (Figure 5.25a-b). Occasionally, cells were seen to have disrupted 
membranes, possibly due to the high treatment concentrations (as seen in Figure 5.25a), but this 
was rarely seen and not correlated to the aggregation of AuNP in the cytoplasm. 
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Figure 5.24: a-b) TEM micrographs of cells treated with AuNP alone. Both images contain insets 
at higher magnifications. 
 
 
Figure 5.25: a-b) TEM micrographs of cells treated with NMC-AuNP. Both images include insets 





Enhanced ~10 nm carbon nanoparticle cellular internalization 
To further probe into the NMC’s ability to deliver an assortment of nanomaterial 
compositions, we analyzed the cellular Raman activity of spectroscopically active CNPs and their 
NMC-CNP counterpart. CNP treatment alone generated high intensity artifacts within the Raman 
Micrographs, but these treatments were not as prevalent or at the magnitude of NMC-CNP 
treatments (Figure 5.26a-c). Furthermore, when compared to bright field images, cells treated with 
NMC-CNP had a majority of the CNP fluorescence intensity come from localized spots within the 
cells (white arrows in Figure 5.26c), while the treatment of CNP alone led to high intensity spots 
localized along the cells perimeter (Figure 5.26b). This difference in localized Raman hot spots 
leads us to believe that the sub-10 nm nanoparticles are aggregating outside the cell on the 
membrane, while the larger NMC-CNP is facilitating a higher degree of high-throughput CNP 
delivery within the cell.  
An averaged spectral analysis of cells did not explicitly reveal the CNP G and D band 
characteristics due to the low laser power needed for sample preservation. However, since Raman 
intensity is directly correlated to the fluorescence intensity caused by the presence of CNP, we can 
discern that the higher Raman readings from NMC-CNP treated cells is due to the high-throughput 
CNP internalization facilitated from the NMC packaging (Figure 5.27). This was also supported 
by Image-J pixel intensity measurements (Figure 5.28) which displayed a notably higher reading 
for NMC-CNP cell treatments.
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Figure 5.26: Raman-generated intensity heat maps (and respective bright field images) of MCF-7 

































Figure 5.28: Bar chart representing pixel intensity per cell of respective treatment formulations 
























Here we have investigated the next generation of nanoparticle delivery by designing 
a nano-architecture for the high-throughput delivery of <10 nm particles, and thus 
alleviating the common complications associated with cellular uptake due to size 
restrictions and systemic clearance. Such a capsule uses simple electro-chemical 
interactions to entrap <10 nm particles within a hydrophobic shell, which is subsequently 
encapsulated into a larger phospholipid capsule. The materials composing the NMC 
architecture were carefully chosen to promote biocompatibility and facile cellular 
internalization as compared to unassisted solid nanoparticle treatments. For a detailed 
investigation into the possible functions of such a versatile capsule, we considered 
propagating the delivery of <10 nm AuNPs, which are adaptable for a multitude of theranostic 
uses. We found that NMC’s (either NMC-AuNP or NMC-CNP) lead to a significantly larger 
quantity of internalized AuNPs among the metastatic cell line MCF-7. Additionally, TEM 
micrographs visually confirmed that cells physically consumed larger clusters of NMC-AuNP, 
with much higher throughput than free AuNP treatment. To expand upon the NMC’s delivery 
ability amongst nanoparticles of different compositions, we encapsulated spectroscopically active 
CNPs and measured their Raman activity. Raman-generated intensity micrographs revealed that 
NMC-CNPs led to a higher degree of intracellular CNP fluorescence, while the treatment of CNP 
alone led to nanoparticle accumulation among the cell’s perimeter to a much lower degree than 
NMC-CNP. Further investigations are warranted for the capability of the NMC to entrap material 
other than solid particles, such as biological matter or small drug molecules. Additionally, the 
NMC’s in vivo adaptability and systemic clearance must be established to translate this novel 




Unless stated otherwise, all materials and reagents were purchased from Sigma–Aldrich, 
St. Louis, MO, and were used without further purification. 
Gold nanoparticle preparation 
AuNPs were prepared based on previous literature.47 A 20 mL aqueous solution containing 
400 µM HAuCl4 and 200 µM Trisodium Citrate (the capping agent) was prepared in a conical 
flask and cooled to 4 °C. Next, the reducing agent, NaBH4, was pre-dissolved in a small volume 
of 4 °C nano pure water (18 MΩ) and quickly added to the solution while stirring to bring the 
NaBH4 concentration of the entire system to 1.45 mM. The solution turned dark purple 
immediately, indicating gold nanoparticle formation (AuNP), then slowly changed to its final red 
color. The AuNP suspension was collected and filtered by a 0.22 μm filter (33mm PVDF 
membrane, Millex, Tullagreen, Ireland). 
Carbon nanoparticle preparation 
CNPs were prepared based on previous literature.36,37 A mixture of agave nectar and 
polyethylene glycol (PEG) (Mn = 10,000) was taken in a glass sample vial at a 1:10 ratio (w/w). 
Nano pure water (18 MΩ) was added to suspend agave and polymer at concentrations of 25 mg/mL 
and 250 mg/ml, respectively. The sample was vortexed to form a homogenous mixture. For CNP 
nucleation, samples were placed on a hot plate surface (maintained at 270 °C) uncapped to allow 
slow evaporation of water. After 45 minutes, the reaction mixture darkened in color. The dark 
suspension was supplemented with nano pure water (18 MΩ) for a final concentration of 36 mg/ml 
and then probe sonicated for 10 minutes (Q700TM, Q sonica Sonicators, CT, USA) (Amp:1, On: 
2 sec, Off: 1 sec) in an ice bath to reduce heat from sonication. The CNP suspension was collected 
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and filtered by a 0.45 μm filter, followed by a 0.22 μm filter (PTFE membrane, Jet Biofil®, 
Guangzhou Jet Bio-Filtration Co., Ltd., Guangzhou, China). 
Inverted micelle nanoparticle transfer 
An equal volume ratio of 16.2 mM of dodecylamine dissolved in chloroform and an 
aqueous suspension of either AuNP or CNP was added into a 1-dram vial and vigorously shaken 
for several seconds to homogenously mix the layers. The vials were then allowed to separate and 
settle for a prolonged period of time. At this point, the nanoparticle variation of choice had clearly 
transferred into the chloroform layer retaining its respective color. 
Nano-MultiCapsule particle formation 
The following method was used to encapsulate the inverted micelle-nanoparticle composite 
into a lipid nanoparticle (NMC-AuNP for AuNP entrapment, or NMC-CNP for CNP entrapment). 
The inverted micelle-nanoparticle composite suspended in chloroform was added to a glass bulb 
along with phosphatidylcholine (PC, Coatsome, NOF Corporation, Tokyo, Japan), 1,2-Dioleoyl-
sn-glycero-3-phosphatidylethanolamine (PE, Cayman Chemical Company, MI, USA), and 
cholesterol at an optimized w/w ratio of 10:9:1:0.5 of dodecylamine:PC:PE:cholesterol. The 
chloroform in the glass bulb was evaporated by a rotary evaporator (RE200, Yamato Scientific 
Co., Ltd. Japan) in a 55 °C water bath to produce a thin film layer of the materials. The sample 
was then placed in a desiccator (Labconco, Kansas City, MO, USA) for 30 minutes. dPBS (pH 
7.4) was added to the bulb at a volume to produce a final concentration of 0.8 mg/ml. The sample 
was subject to probe sonication (Amp: 1, On: 5 sec, Off: 3 sec). The samples were then 
immediately placed in an ice-bath and incubated for one hour at 4 °C. Following incubation, the 
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samples were filtered through a 0.22 μm PTFE syringe filter and dialyzed against a 10,000 
molecular weight cut off cassette (Thermo Scientific Product # 87730, Rockford IL, USA). 
Dynamic light scattering measurements 
Hydrodynamic diameters were determined using a Malvern Zetasizer ZS90 particle size 
analyzer, while the scattered light was collected at a fixed angle of 90°. A photomultiplier aperture 
of 400 µm was used with the incident laser power adjusted to obtain a photon counting rate 
between 200 and 300 kcps. Diameter values depended on measurements whereupon the measured 
and calculated baselines of the intensity autocorrelation function had to agree within ±0.1%. All 
determinations were made in multiples of three consecutive measurements of 15 runs each. 
Determination of electrophoretic surface potential 
Zeta potential (ζ) values for each nanoparticle formulation were determined with a nano 
series Malvern Zetasizer Zeta potential analyzer (Fredrick Seitz Material Research Laboratory, 
University of Illinois at Urbana-Champaign, (MRL facility, UIUC)). Data were acquired in the 
phase analysis light scattering (PALS) mode following solution equilibration at 25 °C when 
calculation of ζ from the measured electrophoretic mobility (μ) employed the Smoluchowski 
equation, which is expressed as: 
Equation 5.2 μ = εζ/η  
where ε and η are the dielectric constant and the absolute viscosity of the medium, respectively.  
Measurements of ζ were reproducible to within ± 2 mV of the mean value given by three 




Raman and FTIR spectroscopy 
All Raman measurements were taken on a Nanophoton Raman instrument (MRL facility, 
UIUC) with a 532 nm wavelength laser. For each spectrum, a grating (600 l mm-1) scan was taken 
over the range of 120–2700 cm-1. Point scans were performed at 0.2% laser power for one minute 
using a 20x objective. An average of 20 spectra were recorded and averaged per sample. For 
Raman micrographs, samples were imaged using line scans at 20% laser power and a 5× objective 
for 20 seconds per scan. 
For FTIR analysis, aqueous suspensions of particles were drop cast onto MirrIR IR-
reflective glass slides (Kevley Technologies, Chesterland, Ohio, USA) and measured using a 
Nicolet Nexus 670 FTIR (MRL facility, UIUC). For each measurement 100 × 100 μm images were 
collected at 1 cm−1 spectral resolution with 64 scans per pixel and a 25 × 25 μm pixel size and 
individual spectra were corrected for atmospheric contributions.  
Transmission electron microscopy imaging 
Two µL of particle suspension was applied to carbon-coated TEM grids. Grids were then 
blotted, air dried, and imaged on a JEOL 2100 Cryo-TEM machine via a Gatan UltraScan 2k × 2k 
CCD camera (MRL facility, UIUC). 
Cell viability assay 
The cytotoxic effect of nanoparticle formulations was investigated with a 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The MCF-7 (human 
estrogen receptor positive breast cancer) cell line was plated on a 96-well plate at a density of 
10,000 cells per well (Greiner CellStar® 96 well plates, Sigma-Aldrich, MO, USA) and exposed 
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to nanoparticle formulations after 24 hours at 37 °C. Followed by a 48 h exposure time, 20 μL 
(5 mg/mL) of MTT solution was added to each well and cells were further incubated for another 4 
hours. After exposure, media was aspirated, and 200 μL of dimethyl sulfoxide (DMSO, ≥99%, MP 
Biomedicals, USA) was added to dissolve formazan crystals. The optical density of samples was 
determined by Synergy HT (BioTek, USA) with a reference wavelength of 570 nm. The following 
equation determined percentage cell viability (Equation 5.3): 





Gold nanoparticle uptake as measured by ICP-OES 
ICP-OES was performed on cells treated with AuNP and NMC-AuNP to measure gold 
content within cells. The MCF-7 cell line was plated on a poly-L-lysine coated 6-well plate at a 
cell density of 1 million cells per well. After 24 hours, cells were treated with duplicates of 
respective formulations for two hours. Before cells were trypsinized and collected, one sample 
from each duplicate was washed three times with heparin sulfate similar to previous reports,46 
while the rest were washed three times with dPBS (pH 7.4). Cells were collected and centrifuged 
to form a cell pellet. Each pellet was then subject to an aqua regia acid degradation and analyzed 
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Throughout this thesis, we have opened a discussion of the complexities that arise upon 
using modern-day treatments for common diseases. Unfortunately, contemporary medicine is still 
imperfect and has plenty of room for improvement. After a thorough literature review, we have 
reason to believe that nanotechnology can be a beacon for innovative treatment solutions and 
diagnostic measures to enhance modern medicine. However, multiple barriers, such as issues with 
biocompatibility, targeting, and retention, all contribute to the overarching theme of poor delivery 
efficiency and slow the adoption of nanotechnology. 
Within this investigation, we addressed the profound issue of nano-delivery efficiency. We 
researched and developed an innovative packaging mechanism using inverted micelle self-
assembly to encapsulate agents, which was followed by lipid wrapping for biocompatible use in 
systemic applications. This simple, 2-step nanoencapsulation technique was tested against an 
assortment of molecular structures and material compositions ranging from inorganic ions to 
organic nanoparticles. With each new encapsulated agent, the NCAP was thoroughly characterized 
for size, stability, structure, encapsulation efficiency, and release profile. These tests were used to 
verify the NCAP’s versatility as a universal and robust encapsulation platform for nano-delivery.  
Then, to apply this technique at the biological level, we thoroughly tested the NCAP in 
applications ranging from imaging to therapy, or both, and for treatment of diseases from cancer 
to bacterial infections. The experiments with NCAPs were carried out in vitro to understand their 
interactions in a biological setting; some were also followed by in vivo experiments to evaluate 
their clinical potential. 
Within our first investigation, we used the nanocapsulation of Cs+ ions to test the highly 
theorized concept of “high-pH therapy” with CsCl supplementation, as well as other possible 
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mechanisms initiated via in vitro and in vivo CsCl delivery. Our investigations showed that neither 
the extracellular delivery of CsCl nor the intracellular delivery if Cs+ ions (facilitated by NanoCs) 
affected intracellular pH, thus disproving the “high-pH therapy.” Furthermore, extracellular 
delivery of CsCl did not initiate programmed cell death. Instead, we found that the internalization 
of Cs+ ions via NanoCs limits glucose internalization, which can function as an alternative 
mechanism for cancer therapy. These findings were gathered using fluorescently labeled glucose 
and ROS assays to monitor cellular starvation and cellular initiated apoptosis. In vivo studies 
showed that xenograft tumors grown in nude mice regressed to a statistically significant level after 
intratumorally injection of NanoCs, as compared to controls. 
To expand our investigations into other disease types, we demonstrated a combinatorial 
approach for bactericidal applications that uses the physically destructive properties of Ag+ ions 
combined with a prodrug derivative of the popular antibiotic drug, levofloxacin. This combined 
approach is strengthened by jointly delivering Ag+ ions and levofloxacin directly to the bacterial 
cell wall. Thorough quantification showed that the combinatorial effects of Ag+ ions and the 
levofloxacin prodrug in the AI-Pro-NPs are additive and yield higher toxicity than each constituent 
alone. After analyzing the integrity of the bacterial DNA and proteins, we showed that the AI-Pro-
NPs exhibited further antibacterial effects at the molecular level. Furthermore, we visualized the 
effective antibacterial properties of Ag+ delivered by the AI-NPs with bacterial TEM, which 
confirmed the bacterial cell wall was, in fact, compromised. Finally, live/dead assays confirmed 
that the combinatorial AI-Pro-NPs had a powerful antibacterial outcome as compared to Ag+ ions 
or the prodrug alone. 
To delve into more complex molecular structures, we propagated the encapsulation of 
multiple dyes and the chemotherapeutic drug doxorubicin and tested their intracellular delivery 
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capabilities on the metastatic breast cancer cell line, MCF-7. Through quantitative and visual data, 
we then compared the NCAPs’ cellular interactions with those of the commonly used liposome 
nanoparticles. Flow cytometry experiments indicated that the NCAPs were 69.93% more effective 
at labeling MCF-7 cells over liposomes, whereas confocal-based imaging and live video 
recordings detailed the NCAPs interactions at the cellular level.  
Finally, we pushed the inverted micelle’s encapsulation limits by assessing its high-
throughput encapsulation and delivery of <10 nm organic carbon nanoparticles and inorganic gold 
nanoparticles. Our aim was to alleviate the common complications associated with cellular uptake 
due to size restrictions and systemic clearance. We found that NMCs led to a significantly larger 
quantity of internalized AuNPs as measured by TEM micrographs. Similarly, the NMC-facilitated 
delivery of spectroscopically active CNPs led to a higher degree of intracellular CNP fluorescence, 
as measured by Raman imaging, while control CNP samples accumulated at the cell’s perimeter. 
Final Note 
In short, by completing these scientific investigations, we have created a novel 
nanoarchitecture and tested its compatibility with a range of chemically and structurally diverse 
theranostic agents. Furthermore, we have determined that this nanoarchitecture is appropriate for 
delivering theranostic agents to target cells and we have evaluated that the encapsulated agents are 
effective at enhancing their intended biological effects as compared to their un-encapsulated 
counterparts. Thus, we have seen that in the field of nanoparticle delivery, the use of inverted 
micelles has shown much promise for robust encapsulation efficiency.  
Further investigations are warranted for the NCAP material and biological capabilities and 
applications. For example, this nanoarchitecture can be used to entrap materials other than those 
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tested here, such as biological matter or radiolabeled compounds. More combinatorial studies 
should also be performed, given the NCAP’s potential to upgrade this novel delivery platform 
towards a multifunctional, all-purpose theranostic solution. Finally, the NCAPs’ long-term effects 
and biodistribution properties in vivo must be established before its translation into clinical use. 
The field of nano-based medicinal treatments is looking bright as indicated by the 51 FDA-
approved nanomedicines. Furthermore, 77 products are currently in clinical trials, with ~40% of 
trials listed in clinicaltrials.gov started in 2014 or 2015.1  This glimpse of nanoparticles in medicine 
offers evidence that there has been an increase in FDA approvals and clinical trials using 
nanoparticles over the past three years. There has also been an increase in the complexity and 
variety of particles used. Bobo et al.1 predict that this trend will continue, and our NCAP design is 
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